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Glutamat-relatert metabolisme i dyremodeller for schizofreni
Schizofreni er en alvorlig psykisk lidelse som preges av psykotiske symptomer som 
vrangforestillinger, hallusinasjoner og andre symptomer som sosial tilbaketrekning og 
svekket sosial fungering. Epidemiologiske studier har vist at livstidsrisikoen er 0,5-1% i det 
meste av verdens befolkning.
Etiologien og patofysiologien til schizofreni er ikke kjent. De to viktigste 
patofysiologiske teoriene for schizofreni har vært den såkalte dopaminteorien og 
glutamatteorien.  Disse predikerer henholdsvis økt aktivitet i dopaminerge systemer og 
redusert aktivitet i visse glutamaterge systemer. Resultater fra studier i den senere tid tyder 
også på at det finnes forandringer i cytoskjellettet ved schizofreni, for eksempel i 
mikrotubuliassosierte proteiner. De fleste schizofrenisymptomer er unike for menneskelig 
atferd. Å kunne reprodusere schizofreni i en dyremodell er derfor vanskelig. Dyremodeller er 
likevel et viktig verktøy for å identifisere patofysiologiske mekanismener bak schizofreni, og 
for å komme fram til nye medisiner. 
Denne avhandlingen inneholder fire publikasjoner hvor vi studerte dyremodeller for 
schizofreni. I tre av dem ble NMDA-reseptorantagonisten MK-801 brukt til å redusere 
glutamaterg nevrotransmisjon i rotter. Tre forskjellige forsøksoppsett ble brukt: En enkelt 
injeksjon av en høy dose MK-801, daglige injeksjoner med høy konsentrasjon i til sammen 
seks dager, og daglige injeksjoner med en lavere dose MK-801 i seks dager. Den fjerde 
studien beskriver glutamatrelatert metabolisme ved ustabile mikrotubili. Dette gjorde vi ved å 
undersøke ”knock out” mus hvor genet for det mikrotubiliassosierte proteinet STOP (Stable 
Tubule Only Peptide) var satt ut av funksjon. 
Vi undersøkte glutamatrelatert metabolisme i alle disse modellene. Hjerneekstrakter 
fra flere hjerneområder ble analysert med HPLC (High Performance Liquid 
Chromatography), 13C- og 1H-magnetisk resonansspektroskopi. Ved å injisere 1-13C merket 
glukose og 1,2-13C merket acetat kunne vi se forskjell på nevron- og astrocyttmetabolisme. 
En enkelt dose med 0,5 mg/kg kroppsvekt MK-801 skapte flest metabolske forskjeller i 
temporal lappen. Her var det økte totale mengder av glutamat og glutamin, og dessuten økt 
innmerkning fra [1-13C]glukose. Vi så liknende forskjeller da vi injiserte 0,1 mg/kg MK-801 i 
flere påfølgende dager. Da rottene derimot ble injisert med 0,5 mg/ MK-801, fant vi 
metabolske forskjeller i cingulate-, retrosplenial- og frontalcortex. Her var det også en økt 
totalmengde av glutamat, men innmerkning fra både [1-13C]glukose og [1,2-13C]acetat var 
redusert i flere metabolitter sammenlignet med kontrolldyrene. Reultater i artikkel 4 viser 
reduserte mengder av både totalglutamin og glutamin merket fra [1,2-13C]acetat i cerebrum til 
STOP ”knock out” mus.
Når vi sammenligner resultatene våre med data fra studier av pasienter med 
schizofreni, ser det ut til at repeterte injeksjoner av en høy dose MK-801, kan være en god 
dyremodell for schizofreni i et tidlig stadium. STOP ”knock out” modellen viser lignende 
metabolske forskjeller som hos pasienter med kronisk schizofreni, og derfor kanskje en god 
dyremodell for mer langtkommen schizofreni.  Resultatene fra studiene i denne oppgaven 
viser at både blokkering av NMDA-reseptoren og ustabile mikrotubili, forstyrrer glutamat-
glutamin syklus, og det er fristende å påstå at interaksjonen mellom astrocytter og nevroner er 
undervurdert i schizofreniforskning.
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acetyl-CoA acetyl coenzym A
AMPA α-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid
ATP adenosine triphosphate
CNS central nervous system
DA dopamine
EAAT excitatory amino acid transporter
FAD flavin adenine dinucleotide
FCR cingulate and the retrosplenial cortices
FID free induction decay
GABA γ-amino-butyric acid
GAD glutamate decarboxylase
GDH glutamic acid dehydrogenase
Gln glutamine
Glu glutamate
GLUT glucose transporter
GS glutamine synthetase
GSH glutathione
GTP guanosine triphosphate
HPLC high performance liquid chromatography
KA kainic acid
KO knock out
MAP microtubule-associated protein
MCT monocarboxylate transporter
MK-801 dizocilpine
NAA N-acetylaspartate
NAD nicotinamide adenine dinucleotide
NMDA N-methyl-D-aspartate
NMR nuclear magnetic resonance
NMRS nuclear magnetic resonance spectroscopy
NO nitric oxide
nOe nuclear Overhauser effect
NOS Nitric oxide synthase
PAG phosphate activated glutaminase
PC pyruvate carboxylase
PCP phencyclidine
PCP phencylidine
PDH pyruvate dehydrogenase
PFC prefrontal cortex
SAT1 system A amino acid transporter 1
SN system N amino acid transporters
STOP stable tubule only polypeptide
TCA tricarboxylic acid
TL temporal lobe
TL temporal lobe
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Summary
Schizophrenia is a clinical syndrome of variable psychopathology, which involves thought, 
perception, emotion, movement and behavior. The cumulative effect of the illness is always 
severe and usually long lasting. Epidemiologic studies indicate that the lifetime expectancy is 0.5-
1% worldwide.
The etiology and pathophysiology of schizophrenia are unknown. The two predominant 
pathophysiological hypotheses of schizophrenia are the dopamine hypothesis and the glutamate 
hypothesis. The former hypothesis states that dopamine neurotransmission is hyperactive in 
schizophrenia, the latter – that there is a hypofunction of glutamatergic neurotransmission in 
some areas of the brain. Recent studies also suggest that schizophrenia is associated with 
cytoskeletal alterations in neuronal architecture, e.g. differences in micro tubule associated 
proteins (MAP). The symptoms of schizophrenia are mostly unique to human behavior. 
Consequently, the exact reproduction of schizophrenia in an animal is not possible. However, 
animal models are important tools for exploring the underlying mechanisms of schizophrenia and 
for designing new therapies. 
The present thesis is based on four publications on animal models of schizophrenia. We used the 
NMDA receptor antagonist MK-801 to induce a state of hypoglutamatergia in rats in the three of 
them. Three different designs were used: injection of a single high dose, repeated high dose 
injections over several days and repeated injections of a lower dose. The fourth study was 
designed to investigate glutamate related metabolism in a state of microtubule instability.  Knock 
out mice were used as a model, in which the gene coding for the microtubule associated protein 
STOP (Stable Tubule Only Peptide) was deleted. 
Glutamate related metabolism was investigated in these models by analyzing brain extracts from 
multiple brain areas, using HPLC (High Performance Liquid Chromatography) and 13C and 1H 
nuclear magnetic resonance spectroscopy. By injecting animals with 1-13C labeled glucose and 
1,2-13C  labeled acetate, the preferential substrates of neurons and astrocytes, respectively, it was 
possible to follow metabolic interactions between astrocytes and neurons.
A single dose of 0.5 mg/kg MK-801 produced predominantly changes in the temporal lobe with 
increased total amounts of glutamate and glutamine, and increased labeling from [1-13C]glucose. 
Similar changes were observed when MK-801 was administered repeatedly at 0.1 mg/kg for 6 
consecutive days and all the metabolic alterations were confined to the temporal lobe. However, 
while 0.5 mg/kg MK-801 was used repeatedly instead of 0.1 mg/kg MK-801, changes were found 
in the cingulate, retrosplenial and frontal cortices. The total amount of glutamate increased in 
those areas together with a decrease in labeling from both [1-13C]glucose and [1,2-13C]acetate in 
several metabolites. In Paper 4 decreased levels of both total glutamine and labeled [4,5-
13C]glutamine were reported in the cerebrum of STOP knock out mice.
Compared to data from studies of schizophrenic patients, our results indicate that repeated 
injections of MK-801 in high doses may be a good model for first episode schizophrenia and the 
STOP KO mouse model show similarities to and may be a good model  chronic schizophrenia. 
Results show that both the NMDA receptor hypofunction and the loss of microtubule stability 
seem to disrupt the glutamate-glutamine cycle, and it can be stated that astrocytic-neuronal 
interactions probably are underestimated in schizophrenia research.
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11 Introduction
1.1 Brain structure and metabolism
1.1.1 Cell types of the brain
Neurons are the cells responsible for the brain’s primary functions and are characterized 
by their ability to send signals over shorter or longer distances. Inter neuronal signals are 
sent mainly via chemical signals, whereas the intracellular signal of the neuron is an 
electric impulse caused by ion movement across the cell membrane, primarily influx of 
Na+ and efflux of K+. The action potential runs down the axon and depolarizes the 
membrane of the synapse. This causes opening of voltage gated ion-channels and an 
increase in intracellular Ca2+ causing release of vesicular neurotransmitters, such as 
glutamate, GABA (γ-aminobutyric acid) and dopamine. The neurotransmitters cross the 
synaptic cleft and binds to specialized receptors on the post-synaptic membrane, where 
this will change the potential of the postsynaptic membrane. Each neuron in the brain can 
be innervated by thousands of synapses, the postsynaptic effects of each active synapse 
can be added together in space and time, and determines whether the postsynaptic neuron 
will generate a new action potential.
However, the neurons cannot do the job alone. They have three main types of helper cells
(glial cells): astrocytes, oligodendrocytes and microglia. In short, oligodendrocytes create 
the myelin around the axons of neurons, whereas microglia have phagocytic properties 
and act as a part of the central nervous system’s immune system (Brodal, 2001).
The role of astrocytes in the central nervous system is slowly gaining more focus.
Traditionally astrocytes have been considered to only have a supportive role for neuronal 
structure (glia = glue), but in recent years far more complex functions with regard to for 
example neurotransmitter and water homeostasis have been unraveled (Nedergaard et al., 
2003).
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and act as a part of the central nervous system’s immune system (Brodal, 2001).
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2Astrocyte morphology is different in distinct areas of the brain. The protoplasmic 
astrocyte has many small processes that spread out in different directions contacting 
neuronal bodies and synapses. Some of these processes have endfeets which line the 
capillaries in the brain. Others line the pia and the ependymal cells bringing the 
astrocytes in close contact to the cerebrospinal fluid. Consequently, the astrocytes are 
well-suited to perform substance exchange between glial cells and neurons, different glial 
cells and glial cells, and blood or cerebrospinal fluid (Brodal, 2001).
It is well established that astrocytes maintain the extracellular concentration of K+ and H+
which are important for neurotransmission (Brodal, 2001). Moreover the astrocytes 
effectively remove several neurotransmitters from the synaptic cleft (Danbolt, 2001).
Astrocytes also synthesize precursors for neurotransmitters (Sonnewald et al., 1993).
More recent studies indicate that astrocytes provide energy substrates to neurons (e.g. 
lactate (Magistretti and Pellerin, 1999)) and are important in brain water homeostasis 
(Nedergaard et al., 2003) and in the maintenance of the blood-brain barrier. There are 
also emerging proofs that they are involved in synaptic modulation and regulation of both 
synaptogenesis and neurogenesis (Ransom et al., 2003).
1.1.2 Neurotransmitters
Chemical neurotransmission is the main way in which a signal is communicated from one 
neuron to another. However, electrical synapses are also present in the brain. In an 
electrical synapse, an ionic current may flow passively through gap junctions, and in that 
way alter the postsynaptic potential. In contrast, chemical synapses enable intercellular 
communication via the release of neurotransmitters. These are chemical agents that are 
stored in vesicles in the presynaptic nerve terminal and released by exocytosis into the 
synaptic cleft upon an action potential. The transmitters diffuse across the synaptic cleft 
and bind to specific receptor molecules on the postsynaptic neuron, usually altering the 
membrane potential by opening or closing ion channels. Neurotransmitters are often 
divided into classical and non-classical transmitters. The classical neurotransmitters are 
all synthesized in the general vicinity of where they are released. Release is calcium 
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3dependent and they are inactivated either by a specific reuptake mechanism or by specific 
enzymes, or both. The classical neurotransmitters  include the biogenic amines, such as 
serotonin and the catecholamines (dopamine, epinephrine and norepinephrine) and the 
amino acid transmitters (glutamate and GABA). Non-classical neurotransmitters include 
peptides (eg. substance P), growth factors and gases (eg. nitric oxide (NO) and carbon 
monoxide) (Deutch et al., 1999).
1.1.3 Neurotransmitter receptors
There are two main types of neurotransmitter receptors: ionotropic receptors and 
metabotropic receptors. The ionotropic receptors are ion channels that will open rapidly 
when a neurotransmitter binds to the binding site. The metabotropic receptors are coupled 
to ion channels via second messengers. Transmitters that activate metabotropic receptors 
produce a postsynaptic response of slower onset and longer duration than that of 
transmitters acting on ionotropic receptors (Waxham et al., 1999).
Glutamate receptors are responsible for mediating most of the excitatory synaptic 
transmission in the central nervous system. There are three main types of ionotropic 
glutamate receptors: AMPA (α-amino-3-hydroxy-5-methyl-isoxazole-4-propionic acid),
kainate and NMDA (N-methyl-D-aspartate) receptors. Six gene families, with two to six 
genes in each family coding for glutamate receptors, are known. When it comes to the 
ionotropic receptors, each gene codes for a subunit. Different subunits are put together to 
form a receptor heteromer. AMPA receptors are formed from subunits from the GluR1-
GluR4 family, and kainate receptors from the GluR5-R7, KA1 and KA2 genes. The 
AMPA/Kainate receptors are permeable to Na+ and to some extent K+ (Waxham et al., 
1999).
The far most studied glutamate receptor is the NMDA receptor. Six genes coding for 
NMDA receptor subunits are known (NR1, NR2A-2D and NR3). The subunits are 
distributed differently and only the NR1 subunit is distributed throughout the brain. In 
contrast to the AMPA/kainate receptors, the NMDA receptors are permeable to both Ca2+
and Na+. They are also voltage dependent. During normal membrane resting potentials 
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4the channel is blocked by a magnesium ion. Accordingly, the channel may only open 
when binding of glutamate and depolarization of the postsynaptic membrane happens at 
the same time. Influx of Ca2+ activate a variety of intracellular processes, therefore 
NMDA receptors  appear to be more directly responsible for aspects of learning and 
memory than other receptors (Waxham et al., 1999). The binding site for 
glutamate/NMDA is also the site where competitive NMDA receptor antagonists bind, 
whereas non-competitve NMDA receptor antagonists like PCP (Phencyclidine), 
Ketamine and MK-801 (Dizocilpine) bind inside the ion channel (Zukin et al., 1987).
Dopamine receptors are metabotropic and are found both pre- and postsynaptically. There 
are five dopamine receptor subtypes which are grouped into the D1-like (D1 and D5) and 
D2-like (D2-D4) receptors. D1-like receptors activate adenylate cyclase, whereas D2-like 
receptors inhibit adenylate cyclase (Waxham et al., 1999).
1.1.4 Glucose metabolism in the brain
Compared to other tissues, the brain is a high energy demanding organ. Although the 
brain accounts for only 2% of the bodyweight, the energy required to maintain brain 
function is almost 20% of an individual’s resting metabolic rate (Attwell and Laughlin, 
2001).
Glucose is the main energy substrate for the brain, but in some circumstances other 
substrates can be utilized. Monocarboxylic acids including lactate and the ketone-bodies 
are important energy-yielding substrates in some instances, especially in neonates. 
The blood-brain-barrier is the interface between the brain tissue and capillary blood. It 
consists of a semipermeable membrane lining either side of the endothelial cells. 
Substrates for energy are taken up by facilitated transport. There are specialised 
transporter for glucose, GLUTs, and monocarboxylic acids, MCTs. 
After uptake into brain cells metabolism of glucose is similar to that in other tissues and 
there are three principal pathways: glycolysis, tricarboxylic acid and the pentose 
phosphate pathway. Glycolysis, which takes place in the cytosol, is the metabolism of 
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5glucose to pyruvate. It results in the net production of two molecules of ATP. Under 
anaerobic conditions, pyruvate is converted to lactate allowing regeneration of NAD+. 
Under aerobic conditions NADH will be reoxidized in the electron transport chain and 
pyruvate can be converted to Acetyl Co-A by the pyruvate dehydrogenase enzyme 
complex (PDH). Acetyl-Co-A condenses with oxaloacetate to produce citrate. This is the 
first step of the TCA-cycle taking place inside the mitochondria of the cell.  Three pairs 
of electrons are transferred from NAD+ to NADH in the cycle, and one pair from FAD to 
FADH2. In addition, 1 GTP is formed. The cycle ends with the formation of oxaloacetate 
from malate (for a review see (Hertz and Dienel, 2002)).
Electrons from the reducing agents NADH and FADH2 are transferred through the 
electron transport chain, which is also called the respiratory chain, to molecular oxygen. 
This process is coupled to H+ translocation across the inner mitochondrial membrane 
forming an electrochemical gradient. The electrochemical gradient drives the ATP 
synthase forming ATP. The quantity of ATP generated from this process is dependent 
upon coupling between O2 consumption and ATP formation. Since every FADH2 or 
NADH molecule oxidized in the respiratory chain, produces essentially two or three 
molecules of ATP, respectively, the complete oxidation of one glucose molecule in a 
neural cell generates up to 34 ATP molecules. This represents a vast improvement over 
the two ATP molecules produced by anaerobic metabolism in glycolysis, a circumstance 
that makes the TCA cycle the most efficient cerebral bioenergetic process under aerobic 
conditions (Smith and Morowitz, 2004).
Besides being the main energy yielding metabolic pathway in the brain, the TCA cycle 
also has an important role in providing intermediates for many cerebral biosynthetic 
processes and neurotransmitters such as glutamate and GABA. (Gruetter, 2002; Owen et 
al., 2002) Loss of TCA cycle intermediates occurs when a-ketoglutarate is converted into 
glutamate and hence into GABA (in GABAergic neurons) and used in neurotransmission. 
To compensate for the loss of TCA cycle intermediates due to release of glutamine to the 
blood or decarboxylation of a four carbon unit, synthesis from precursors that are not 
TCA cycle intermediates themselves are needed. This kind of reaction is called 
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6anaplerosis. The main anaplerotic enzyme in the brain is pyruvate carboxylase (PC). 
Anaplerotic carboxilation can also be carried out by phosphoenolpyruvate carboxykinase
and malic enzyme, though they function mostly in the decarboxylation mode(Patel, 1974,
Salganic.L and Koeppe, 1968). Pyruvate carboxylase is a mitochondrial enzyme and
catalyzes the formation of oxaloacetate from pyruvate and HCO3- . PC has been shown 
by both biochemical and immune cytochemical methods to be expressed by cultured 
astrocytes, but not by cultured neurons(Shank et al., 1985, Yu et al., 1983)
1.1.5 Glutamine-glutamate cycle and compartmentation of brain 
metabolism
In the 1960s, after intracerebral administration of radiolabeled 14C-acetate, a higher 
specific radioactivity in glutamine than in its precursor glutamate was found(Berl, 1965,
Berl and Clarke, 1969, Waagepetersen et al., 2003). These findings could only be 
explained through the existence of two slowly exchanging pools of glutamate, denoted 
then as ‘‘large’’ and ‘‘small,’’ which exchanged radioactivity with ‘‘small’’ and ‘‘large’’ 
glutamine pools, respectively (Rodrigues and Cerdan, 2007). Soon, the ‘‘large’’ and 
‘‘small’’ glutamate and glutamine pools were associated with the operation of the 
‘‘energy’’ and ‘‘synthetic’’ TCA cycles, proposed to represent the neuronal and glial 
compartments, respectively. Subsequently, both cycles were connected by transfers of 
glutamate from the neuronal to the glial cycle, and glutamine in the opposite direction. 
The ‘‘glutamate–glutamine cycle’’ was conceived as a mechanism to replenish glutamate 
losses in the neurons during neurotransmission (van den Berg and Garfinkel, 1971).
Glutamate must be removed from quickly from the entire extracellular space. This is 
required for a high signal-to-noise ratio in synaptic transmission. Furthermore, excessive 
activation of glutamate receptors is toxic (so-called exitotocxicity) and glutamate 
receptors are found on most of the cellular elements (dendrites, nerve terminals, neuronal 
cell bodies as well as glial cells (Choi, 1992). The only rapid way of removing glutamate 
from the extracellular ﬂuid surrounding the receptors is by cellular uptake (Danbolt, 
2001). Glutamate uptake is accomplished by means of glutamate transporter proteins 
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7which use the electrochemical gradients across the plasma membranes as a driving force 
for uptake (Danbolt, 2001). Both neurons and glial cells express glutamate transporters.
Figure 1 The glutamate-glutamine cycle. Glutamate is formed from α-ketoglutarate. After 
vesicular release from presynaptic nerveendings and binding to glutamate receptors on the 
postsynaptic membrane, glutamate is predominantly taken up by astrocytes via specialized 
transporter proteins. Here glutamate can be converted into glutamine, wich is not neuroactive and 
transported to neurons where it is converted back to glutamate and can be packed into vesicles 
for reuse as neurotransmitter. Also notice that the enzymes pyruvate carboxylase and glutamine 
synthetase are not present in neurons. Abbreviations:Gln, glutamine; Glu, glutamate; GS, 
glutamine synthetase; PAG, phosphate activated glutaminase; GDH, glutamic acid 
dehydrogenase; TCA, tricarboxylic acid cycle; EAAT, excitatory amino acid transporter; SN1, 
system N amino acid transporter 1; SAT1, system A amino acid transporter 1
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8Reuptake and reuse of glutamate as neurotransmitter is important because glutamatergic 
neurons, in contrast to astroglia, do not express pyruvate carboksylase as outlined above.
Thus neurons cannot synthesize glutamate de novo from metabolites in the TCA cycle 
without causing a net loss of these metabolites. After uptake to presynaptic nerve
endings, the reuse is straightforward as glutamate can be directly transported into 
vesicles. The first step in the recovery of glutamate uptake in astroglia is mediated by 
glutamate transporters EAAT (excitatory amino acid transporter) 1 and 2. (Danbolt, 
2001). After uptake into astrocytes, glutamate may be transformed to glutamine by the 
ATP-dependent, astrocyte-speciﬁc enzyme glutamine synthetase (Martinez-Hernandez et 
al., 1977, Laake et al., 1995). Glutamine can be released from astroglia to extracellular 
fluid via the glial glutamine transporter SN1 (system N amino acid transporter 1).  
Glutamine is then taken up by the presynaptic neuron through the neuronal glutamine 
transporter SAT1 (system A amino acid transporter 1) and converted back to glutamate 
by phosphate-activated glutaminase (PAG) (Kvamme et al., 2001, Chaudhry et al., 2002).
1.1.6 Cytoskeleton, Microtubuli and MAPs
The cytoskeleton is the “backbone” of the cells and helps maintain cell shape.  It is 
formed by three different structural proteins in all eukaryotic cells: actin (micro) 
filaments, intermediate filaments and microtubules. In the neurons, actinfilaments are 
found the axons and are especially important for neurogenesis during development of the 
nervous system. High concentration of the intermediate filaments is also found in the 
axons. Microtubules are important in neurogenesis and synaptogenesis, and are found in 
all neural projections. They are involved in both anterograde and retrograde transport of 
organelles, proteins and neurotransmitters. Moreover, actin filaments and microtubules 
are involved in moving vesicles in presynaptic nerve terminals close to the cell 
membrane, and in this way are essential to neurotransmitter release (Brodal, 2001). 
Microtubules, the main cytoskeletal components, are long protein polymers assembled 
from subunits formed by alpha and beta tubulins. They maintain a dynamic equilibrium 
between polymers and dimers through polymerization–depolymerization cycles. 
Microtubule-associated proteins (MAPs) that bind along the sides of microtubules 
regulate these processes (Shimizu et al., 2006).
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91.2 Schizophrenia
Schizophrenia is a clinical syndrome of variable psychopathology, which involves 
thought, perception, emotion, movement and behavior. The expression of these 
symptoms varies across patients and over time, but the cumulative effect of the illness is 
always severe and usually long-lasting. Epidemiologic studies indicate that the lifetime 
expectancy of schizophrenia is 0.5-1% worldwide. The morbidity often persists 
throughout life, and has devastating consequences for both the afflicted individuals and 
their families. The symptoms of schizophrenia are commonly categorized into positive, 
negative and cognitive. Positive symptoms are those symptoms that involve an excess of 
normal experiences and behavior. The senses may operate at a heightened and excessive 
state, which can result in hallucinations and delusions. Negative symptoms, on the other 
side, reflect a loss of normal functions and in consequence can lead to flattened affect, 
impaired attention, social withdrawal and poverty of speech.
1.2.1 Neurotransmitter hypothesis of schizophrenia
1.2.1.1 Dopamine hypothesis
The most studied hypothesis of schizophrenia is the dopamine hypothesis. In 1952 it was 
discovered that the drug chlorpromazine, which was at that time used by surgeons, had an 
antipsychotic effect. Within a few years, chlorpromazine became widely used as an 
antipsychotic. During the 1960s and -70s, the scientists found out that the effect of 
chlorpromazine and other antipsychotics was due to the blockade of dopamine receptors, 
or more specific the D2 receptor subtype (Carlsson and Lindqvist, 1963). This led to the 
dopamine hypothesis which in its simplest form proposes that dopamine 
neurotransmission is hyperactive in schizophrenia (Carlsson, 1978). The hypothesis was 
further supported by the fact that exposure to amphetamine, which is an indirect 
dopamine (DA) agonist, produces psychosis. 
Although psychosis can be very effectively treated by dopamine antagonists, the negative 
and cognitive symptoms of the illness are generally resistant to treatment by 
antipsychotics. Functional brain imaging studies suggested that these symptoms may be 
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associated with a dysfunction of the prefrontal cortex (PFC) (Weinberger, 1987). This led 
from a theory of exclusive hyperdopaminergia to a theory of combined subcortical hyper-
and prefrontal hypodopaminergia. The so-called revised dopamine hypothesis of 
schizophrenia predicts that subcortical mesolimbic DA projections may be hyperactive, 
resulting in increased stimulation of D2 receptors and positive symptoms, while 
mesocortical DA projections to the PFC may be hypoactive, resulting in reduced 
stimulation of D1 receptors and cognitive impairment (Moghaddam et al., 2003). The 
dopamine hypothesis has for a long time only been based on indirect evidence . Only in 
the last decade has it received more direct support. Neuroimaging studies have now 
shown that amphetamine-induced dopamine release is elevated in drug-naive 
schizophrenic patients compared to healthy volunteers (Abi-Dargham et al., 1998, Breier 
et al., 1997). However, the dopamine hypothesis alone has not made it possible to explain 
the patophysiology of schizophrenia.
1.2.1.2 Glutamate hypothesis
Another hypothesis of schizophrenia arose in the early 1980s: It was found that the 
psychotomimetic drug PCP, first developed as a general anesthetic in the 1950s, was a 
potent antagonist of the NMDA subtype of glutamate receptors (Anis et al., 1983, Lodge 
and Anis, 1982). Subanesthetic doses of PCP produce symptoms in healthy persons that 
closely resembles those seen in schizophrenia. The symptoms include both positive, 
negative and cognitive aspects (Luby et al., 1959). On the basis of these findings, a 
theory of hypoglutamatergic neurotransmission in schizophrenia was proposed (Javitt and 
Zukin, 1991). Studies showing abnormal expression of glutamate receptors in some brain 
areas of schizophrenic patients provided further support for a hypoglutamatergic theory 
of schizophrenia. Reductions of NR1, NR2B and NR2CR subunits of the NMDA 
receptor in the thalamus were reported (Ibrahim et al., 2000). Down-regulation of NR1 
was also reported in the superior temporal gyrus and hippocampus (Gao et al., 2000, 
Sokolov, 1998). Reduced expression of AMPA- and kainate receptor subunits were also 
found (For a review see (Meador-Woodruff and Healy, 2000)). Moreover, the most 
known susceptibility genes for schizophrenia act on glutamatergic synaptic transmission 
(Harrison and Weinberger, 2005). A selective metabotropic glutamate 2/3 receptor 
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agonist has shown antipsychotic potential in animal studies (Rorick-Kehn et al., 2007,
Moghaddam and Adams, 1998). Recently, the substance has been tested on schizophrenic 
patientst in a phase 2 clinical trial. Improvements in both positive and negative symptoms 
have been found, providing further strength to the glutamate hypothesis (Patil et al., 
2007).
1.2.1.3 Integrative hypothesis of dopamine and glutamate
It has been suggested that the dysregulation of dopamine transmission in schizophrenia 
may be secondary to alterations in glutamatergic NMDA receptor-mediated transmission 
(Carlsson et al., 2004, Olney and Farber, 1995). A SPECT (single photon emission 
computed tomography) study showed that healthy volunteers who received ketamine, the 
amplitude of amphetamine-induced dopamine release was significantly enhanced 
compared to control conditions (Kegeles et al., 2000). Thus the elevated dopamine 
release seen in schizophrenic patients after amphetamine administration may well be 
secondary to a failure in glutamatergic control of dopamine neurons. This hypothesis is 
supported by experimental studies in rats (Miller and Abercrombie, 1996).
1.2.2 Metabolic and mitochondrial dysfunction in schizophrenia
Brain metabolism can be measured directly by fluorodeoxyglucose (FDG)-PET or 
indirectly by blood-flow or haemoglobin oxygen saturation. Already in 1974, a relative 
decrease of cerebral blood flow in the frontal cortex was found in patients with 
schizophrenia. The phenomenon was termed hypofrontality (Ingvar and Franzen, 1974, 
Cantorgraae et al., 1991). At a later time, several studies, in which different techniques 
were used, showed alterations in cerebral blood-flow and brain metabolic rates, and 
confirmed the relative hypofrontality (For a review see (Buchsbaum and Hazlett, 1998))
Several authors also observed alterations in brain metabolic rates in other brain regions, 
which led to the suggestion of impairment in the frontostriatal-thalamic circuitry in 
schizophrenia rather than only prefrontal or frontal dysfunction (Buchsbaum and Hazlett, 
1998, Chua and McKenna, 1995).
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Brain energy metabolism in patients with schizophrenia was also evaluated by using 
31phosphorous magnetic resonance spectroscopy (31P-NMRS) to measure phospholipids 
and high-energy phosphates. A decrease in phosphodiester values and an increased ratio 
of phosphomonoesters/ phosphodiesters was observed in the frontal cortex of subjects
with schizophrenia compared to control subjects (Volz et al., 2000). Decreased levels of 
ATP in the basal ganglia and the temporal lobes of subjects with schizophrenia were also 
observed with the help of 31P-NMRS (Kegeles et al., 1998).
These findings has led to the hypothesis of impaired energy metabolism and impaired 
mitochondrial function in schizophrenia (Ben-Shachar, 2002, Ben-Shachar, 2009, Rezin 
et al., 2009, Scaglia, 2010). Mitochondrial morphological abnormalities in schizophrenia
were demonstrated by microscopic analysis of autopsy specimens. Electron microscopic 
analyses of post-mortem specimens from the anterior limbic cortex and the caudate 
putamen nucleus showed mitochondrial deformation and reduced density throughout the 
neuropil in schizophrenic patients (Uranova and Aganova, 1989). Ultra structural studies 
in the caudate nucleus and the prefrontal cortex showed decreased volume density of 
mitochondria in oligodendrogliocytes in subjects with schizophrenia(Uranova et al., 
2001) Later the same group suggested a progressive disturbance in astrocytes due to 
deficits in mitochondria (Kolomeets and Uranova, 2010).
Both studies of enzyme activity and genetic studies implicate abnormalities in oxidative 
phosphorylation in schizophrenia. Several studies have suggested that decreased activity
of complex I and complex IV of the electron transport chain could underlie the 
pathological mechanism of schizophrenia (Ben-Shachar, 2002, Cavelier et al., 1995,
Mulcrone et al., 1995, Scaglia, 2010). Altogether there is substantial evidence for a
disrupted brain energy metabolism in schizophrenia.
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1.2.3 Animal models of schizophrenia
1.2.3.1 General
Schizophrenia is a complex syndrome of unknown etiology, which is defined by its 
clinical symptoms.  Most of these symptoms are unique to human behavior. 
Consequently, it is not possible to exactly reproduce schizophrenia in an animal. 
However, animal models are important tools in exploring the underlying mechanisms of 
schizophrenia and in designing new therapies. There are three different criteria that are 
important when establishing and evaluating an animal model of any disease: 
1) Construct validity: The model reconstructs the etiology and pathophysiological 
mechanisms of the disease.
2) Face validity: The model mimics phenomenology e.g. symptoms of schizophrenia. 
3) Predictive validity: The model predicts responsiveness to available treatments for that 
disease in humans (e.g. antipsychotic drugs) (Lipska et al., 2003).
Traditionally, most animal models of schizophrenia, on the basis of the dopamine 
hypothesis of schizophrenia, have focused on the dopamine neurotransmitter. The focus 
has recently shifted and the novel models can be categorized into three different 
approaches:
1) Neurodevelopmental models which test the hypothesis that schizophrenia is caused by 
a defect in cerebral development. 
2) Glutamatergic hypofunction models which are  based on the glutamate hypothesis of 
schizophrenia. 
3) Genetic models which use targeted gene deletion or gene transfer techniques to 
investigate susceptibility genes, that is genes that are associated with a higher risk for 
developing schizophrenia in humans (Lipska et al., 2003).
1.2.3.2 The MK-801 model of schizophrenia
The glutamate hypothesis has been one of the most studied and promising hypothesis of 
schizophrenia in the recent years. As described above, the hypothesis is based on the 
observation that PCP causes schizophrenia like-symptoms in humans. Not only does PCP 
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mimic the positive symptoms of schizophrenia, but also produce the whole spectrum of 
symptoms including negative and cognitive symptoms. PCP was found to be a non-
competitive NMDA receptor antagonist binding to a binding site inside the ion channel 
(Zukin et al., 1987). It was later shown that other NMDA receptor antagonists also had 
psychotomimetic properties. The PCP psychosis is therefore not a PCP-specific 
phenomenon, but rather a phenomenon resulting from the effective NMDA receptor 
blocking (Olney and Farber, 1995). One of the best characterized non-competitive 
NMDA receptor antagonists that binds to the PCP binding site, is MK-801 (Dizocilpine; 
[5R, 10S]-[+]-5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine). It is a 
more selective and a more potent NMDA receptor channel blocker than PCP (Carlsson et 
al., 2001), and therefore a good tool to study hypoglutamatergia or more specific NMDA 
receptor hypofunction in animals (Olney and Farber, 1995) MK-801 causes behavioral 
changes in rodents such as hypermobility, head weaving and ataxia (Loscher et al., 1991).
MK-801 also induces social withdrawal (Rung et al., 2005). The model also possesses 
predictive validity, as it distinguishes between atypical and typical antipsychotics based 
on their ability to suppress abnormal pre frontal cortex activity (Homayoun and 
Moghaddam, 2007).
1.2.3.3 STOP(MAP 6) knock out mouse
Cumulative evidence suggests that schizophrenia is associated with cytoskeletal 
alterations in neuron architecture. Affected neurons lose synaptic connectivity and the 
ability to transmit incoming axonal information to the somatodenritic domain (Shimizu et 
al., 2006). An increasing number of studies have reported altered expressions of MAPs, 
particularly of MAP2, in brains of schizophrenic patients (Anderson et al., 1996, Cotter et 
al., 2000, Rioux et al., 2003, Jones et al., 2002).
MAP6, also called STOP (Stable Tubule only Polypeptide) protein, is a MAP involved in 
the cold stability of microtubules, synaptic plasticity and neurotransmission (Andrieux et 
al., 2002). Knockout (KO) mice of STOP protein have been proposed to be a 
“meaningful model for the study of the pathophysiology of schizophrenia” (Brun et al., 
2005). The deletion of the STOP protein leads to a decrease in synaptic vesicle density in 
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hippocampal CA1 terminals, impaired long term potentiation and depression at the level 
of Schaffer collaterals-CA1 pyramidal cell synapses (Andrieux et al., 2002). STOP KO 
mice are also characterized by disorganized activity with frequent shifts between 
hyperlocomotion and prostration, anxiety-related behavior, inability to perform object 
recognition tasks and social withdrawal. These behavioral disorders can be alleviated by 
long-term treatment with antipsychotics (Andrieux et al., 2002, Begou et al., 2008, 
Powell et al., 2007). STOP KO mice exhibit in addtion increased dopaminergic 
neurotransmission and increased efflux of dopamine in the nucleus accumbens upon 
stimulation (Brun et al., 2005). Interestingly, the human STOP gene, located at position 
11q14, lies within a region which has been linked to major mental diseases including 
schizoid disorders (Brzustowicz et al., 2000, Holland and Gosden, 1990)and a recent 
study indicates that STOP gene is upregulated in the prefrontal cortex of patients with 
schizophrenia (Shimizu et al., 2006).
1.3 Nuclear magnetic resonance spectroscopy
1.3.1 Basic principles of NMRS(Hornak, 1997-2008, Derome, 1987)
Spin is a fundamental property of elementary particles like electrical charge or mass and
protons, electrons, and neutrons possess spin. Two or more particles with spins having 
opposite signs can pair up to eliminate the observable manifestations of spin. Only nuclei 
that possess a net spin and charge, i.e. a net magnetic moment, can be studied by NMRS. 
This includes 1H, 13C, 7Li, 19F, 23Na, 31P. The present thesis is based on the work in which 
both 1H- and 13C-spectroscopy were used.
When a nucleus with a net spin is subjected to an external magnetic field, it will be 
aligned either with or against the magnetic field. It will also precess about the magnetic 
field. This is called the Larmor precession, and the frequency of this precession is called 
the Larmor frequency. The nuclei that are oriented parallel to the magnetic field exist in a 
lower energy state than the nuclei aligned against the magnetic field. According to 
Boltzmann statistics the number of spins at the lower energy level slightly outnumber
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those at the higher energy level. A nucleus can undergo a transition between the two 
energy states by absorbing electromagnetic radiation. The radiation (which is in the radio 
frequency range) has to match the energy difference of the energy levels in order for it to 
happen. This takes place when the radio frequency is the same as the Larmor frequency. 
After the transition to the higher energy state, the nuclei will make a transition from the 
higher to the lower energy state and thus emit energy. This emission is the NMR signal.
The phenomenon of nuclear magnetic resonance as described above is utilized in an
NMRS(nuclear magnetic resonance spectroscopy) experiment by applying a large 
external magnetic field, B0, to the sample. In addition to this static magnetic field, another 
magnetic field (B1) in the form of electromagnetic waves is applied perpendicular to B0.
When B1, which is a radio frequency pulse with the Larmor frequency, is applied to the 
sample, a transition between the two energy states is induced. When B1 is switched off, 
relaxation to equilibrium occurs. The relaxation is characterized for each nucleus by two 
time constants T1 (longitudinal relaxation) and T2 (transverse relaxation). The nuclei 
emit energy in the form of radiofrequency during the relaxation process. The emitted 
energy is detected as a signal called the free induction decay (FID) by a detection coil. To 
be able to analyze the data the FID is converted into an NMR spectrum by a Fourier 
transform, which is an operation that converts functions from time to frequency domains.
The resonance frequency of the nucleus is dependent on the magnetic field. The electrons 
of the atom will also circulate in the applied magnetic field and this circulation causes 
small magnetic fields. The total magnetic field experienced by a nucleus includes these
local magnetic fields induced by electrons in the chemical bonds. This will slightly 
change the resonance frequency of the nucleus. The variations in the nuclear magnetic 
resonance frequencies of the same kind of nucleus are due to variations in the electron 
distribution. This phenomenon is called the chemical shift. The chemical shift makes it 
possible to distinguish between different molecules, and also between different atoms in 
the same molecule, in an NMR-spectrum. Nuclei with net spin that are close to one 
another exert an influence on one another's effective magnetic field. If the distance 
between non-equivalent nuclei is less than or equal to three bond lengths, this effect is 
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observable. This effect is called spin-spin coupling or J-coupling and is visible in the 
NMR spectrum as multiplets. For an example of homonuclear (between the same type of 
nuclei) spin-spin coupling see Figure 1 which depicts a 13C NMR spectrum. The singlet 
of peak 8 represents [4-13C]glutamine where only the carbon in the fourth position is 13C 
and the doublets represents [4,5-13C]glutamine where the carbons in both fourth and fifth 
position are 13C. There can also be spin-spin couplings between a 13C nucleus and its 
neighboring 1H nuclei (heteronuclear coupling), which consequently produces multiplets 
in the spectrum. This makes the spectrum hard to analyze. To avoid this, proton 
decoupling is applied. Proton decoupling is done by using a small powered B1 pulse with 
the Larmour frequency of the 1H nuclei. Due to the nuclear Overhauser effect (nOe), 
which has not been explained here, proton decoupling will make peaks in the 13C spectra 
higher. While analyzing the spectra, the nOe is corrected for.
1.3.2 13C NMRS and 13C labeling patterns
13C has a natural abundance of only 1.1 %, which makes detection difficult. 13C NMRS 
is of limited use in studies of endogenous metabolites unless the compounds occur in 
large amounts. However, the low natural abundance can be used as an advantage in the 
study of metabolic pathways (for review, see (Bachelard and Badar-Goffer, 1993)). 13C
labeled metabolic precursors can be added to cell cultures or injected into research 
animals and humans. As a result, detection by NMRS and quantification of 13C atoms and 
their position in different metabolites is possible. 13C NMRS is in this way a very good 
tool to study metabolic pathways and trafficking of metabolites between different 
compartments of brain metabolism. In the studies that constitute this thesis, 13C labeled 
glucose and acetate were injected into rats and 13C NMRS was done on brain extracts 
from different brain regions. In order to interpret the NMRS-spectra and understand the 
results obtained from these spectra, it is necessary to know the relevant metabolic 
conversions of [1-13C]glucose and [1,2- 13C]acetate.
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and the doublets represents [4,5-13C]glutamine where the carbons in both fourth and fifth 
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decoupling is applied. Proton decoupling is done by using a small powered B1 pulse with 
the Larmour frequency of the 1H nuclei. Due to the nuclear Overhauser effect (nOe), 
which has not been explained here, proton decoupling will make peaks in the 13C spectra 
higher. While analyzing the spectra, the nOe is corrected for.
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Figure 2: Example of part of a 13C NMR spectrum of cerebrum extract from mice injected with 
[1,2-13C]acetate and [1-13C]glucose. Peak assignments; 1: glutamate C-2; 2: glutamine C-2; 3: 
aspartate C-2; 4: aspartate C-3; 5: GABA C-2; 6: succinate C-2/C-3; 7: glutamate C-4; 8: 
glutamine C-4; 9: glutamate C-3; 10: glutamine C-3; 11: GABA C-3; 12: N-acetylaspartate C-3; 13: 
lactate C-3; 14: alanine C-3. Note that the singlets are mostly derived from [1-13C]glucose and the 
doublets in the spectrum from [1,2-13C]acetate.
Acetate is selectively taken up by astrocytes, through a specialized transport system
(Waniewski and Martin, 1998), which is absent or less active in neurons, whereas glucose 
is thought to be metabolized more in the neuronal tricarboxylic acid cycle. By using 13C 
NMRS, it has been calculated that 65% of acetyl CoA derived from glucose is 
predominantly metabolized in the neuronal TCA cycle (Qu et al., 2000). Thus, by 
simultaneous injection of [1-13C]glucose and [1,2-13C]acetate followed by NMRS 
analysis of brain extracts, information about neuronal and astrocytic metabolism can be 
obtained in the same animal.
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Injection of 13C labeled glucose and acetate leads to efficient labeling of many 
metabolites in the brain. They are visible in the spectrum of Figure 2. Label from 
[1-13C]glucose can be quantified by analyzing the singlet peaks in the spectra. The 
doublets are mostly derived from [1,2-13C]acetate and thus astrocytic metabolism. [1-
13C]glucose is converted to pyruvate via glycolysis and can form [3-13C]alanine and [3-
13C]lactate. Pyruvate can enter the TCA cycle via [2-13C]acetyl CoA. This will lead to the 
formation of [4-13C]glutamate and glutamine or [2-13C]GABA. Alternatively, pyruvate 
can be carboxylated by pyruvate carboxylase (PC) to oxaloacetate, which will lead to the 
synthesis of [2-13C]glutamate and glutamine or [4-13C]GABA. [1,2-13C]acetate can also 
be converted to acetyl CoA. However, the product, i.e. [1,2-13C]acetyl CoA, will have
two 13C atoms (Figure 3), which will result in doublet formation. Thus [4,5-13C]glutamate
and glutamine or [1,2-13C]GABA are formed. Since both acetyl CoA and oxaloacetate 
can be labeled or unlabeled, the number of possible isotopomers of the metabolites 
derived from the TCA cycle is large. Only compounds derived from the first turn are 
represented in Figure 2. By comparing the doublets with singlets, it can be shown that 
glutamine is labeled more from [1,2-13C]acetate (doublet) than [1-13C]glucose (singlet).
The opposite is the case for glutamate and GABA. Lactate, alanine, N-acetylaspartate 
(NAA) and succinate are mainly labeled from glucose. 
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Figure 3: Schematic representation of 13C labeling of glutamate, glutamine, GABA and aspartate 
originating from [1-13C]glucose (a) or [1,2-13C]acetate (b). Filled circles represent 13C and empty 
circles 12C. TCA, tricarboxylic acid cycle; Glu, glutamate; Gln, glutamine.
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1.4 High performance liquid chromatography (Greibrokk et al., 1998)
High-performance liquid chromatography is a technique that can separate a mixture of 
compounds. It utilizes a mobile phase and a stationary phase. The analytes are dissolved 
in the mobile phase which is a liquid. A pump moves the analyte and the mobile phase 
through the stationary phase which in the case of HPLC is contained in a column. The 
different compounds will be separated according to their chemical properties. The time it 
takes for each compound to be moved through the column is dependent on the relative 
affinity towards the column material and the mobile phase. On the other side of the 
column, the compounds are detected by a detector at their specific retention times. There 
are several methods for detecting the compounds. In the four studies presented in the 
thesis, aminoacids were detected by a fluorescence detector after derivatization with 
o-phthalaldehyde. An electrochemical detector was used for the analysis of 
catecholamines.
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2 Aims of study
The aims of the studies were to answer the following questions:
1. What is the effect of a single dose of the NMDA receptor antagonist MK-801 on 
glutamate related metabolism, and is it a good animal model of schizophrenia?
2. Do repeated injections of MK-801 over a longer period of time model 
schizophrenia better than a single dose of MK-801?
3. What is the effect of microtubule instability on glutamate related metabolism? Is 
the STOP knock out mouse a good schizophrenia model?
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3 Methods
3.1 Experimental Procedures with Animals
3.1.1 Rats injected with MK-801
Three different studies were performed using systemic injections of MK-801 as an animal 
model of schizophrenia. All experiments were performed in accordance to internationally 
accepted guidelines and permission from the Norwegian Animal Reasearch Authority 
was obtained. Prior to experiments and between each procedure, the animals had free 
access to food and water and were kept at a light/dark cycle of 12 h, humidity 60%, 
temperature 22ºC. In the first study (Paper 1) the animals in the treatment group received 
a solution consisting of MK-801 (0.5 mg/kg), [1-13C]glucose (543 mg/kg) and [1,2-
13C]acetate (504 mg/kg), the control animals  were given a solution with the same 
concentration of [1-13C]glucose and [1,2-13C]acetate in sterile water, but without MK-
801. Animals in both groups were injected intraperitoneally with 10 ml/kg of the 
respective solutions. Twenty minutes after the injection the animals were killed by 
decapitation and the heads snap frozen in liquid nitrogen, and later stored at -80ºC. Brains 
were removed, and two different areas of each hemisphere were dissected. The first area 
consisted of both the cingulate and the retrosplenial cortices (this is from now on referred 
to as FCR). The second area, which will be referred to as the temporal lobe (TL), was 
dissected using a horizontal cut from the most lateral point of the hemisphere extending 
approximately 3 mm medially and a second sagittal cut extending ventrally through the 
whole brain. This resulted in a sample including the temporal cortex, the piriform cortex, 
the entorhinal cortex, the amygdala and parts of the hippocampus. The dissection lasted 
max. 3 min and was performed on ice with the brains still frozen. After dissection, brain 
tissue was homogenized in 7% (w/v) perchloric acid and centrifuged at 4.000 g for 5 min. 
The procedure was repeated with distilled H2O. The supernatants were pooled and 
neutralized with 1 M KOH followed by lyophilization.
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In the two studies with repeated MK-801, saline or MK-801 (0.5 mg/kg body weight in 
Paper 3 and 0.1 mg/kg in Paper 2) were injected intraperitoneally once a day for six days. 
Hyperlocomotion was assessed by observing rats for 30 minutes after injection and 
counting how often rats passed completely one of the two imaginary lines dividing the 
cage in four equal quarters. The last MK-801 injection was given together with [1-
13C]glucose and [1,2-13C]acetate and twenty minutes later animals were decapitated. The 
rest of the procedures were performed as described for the first study.
3.1.2 STOP KO mice
STOP KO male mice (STOP-/-), heterozygous (STOP+/-) and control wild type
littermates (STOP+/+), 15 week-old, were used. Mice were housed eight per cage and 
maintained in quiet, uncrowded facilities (room temperature of 22ºC ± 1°C) on a 12 hour 
light-dark schedule (7:00 a.m., lights on), humidity 60%, and given unlimited access to 
lab chow and water. All animal experimentation was performed in accordance with the 
rules of the European Committee Council Direction of November 24, 1986 (86/69/EEC) 
and the French Department of Agriculture (License N°67-97). 
The animals (10 in each group) were injected intraperitoneally with [1-13C]glucose 
(543mg/kg, 0.3 M solution) and [1,2-13C]acetate (504mg/kg, 0.6 M solution) followed by 
decapitation fifteen minutes later. The heads were immediately frozen in liquid nitrogen 
and stored at -80ºC. The brains were removed from the slightly thawed skull, and,
because of their small size and limitations of sensitivity of the method, the 
forebrain/midbrain (cerebrum) including cerebral cortex and subcortical regions was 
used. The brainstem and the cerebellum were discarded. The tissue was homogenized in 
7% (w/v) perchloric acid and centrifuged at 4,000 g for 5 min. The procedure was 
repeated, the supernatants pooled and neutralized with 1 M KOH followed by 
lyophilization.
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3.2 High Performance Liquid Chromatography
Amino acids in cell extracts and medium were quantified by HPLC on a Hewlett Packard 
1100 system (Agilent Technologies, Palo Alto, CA, USA). The amino acids were pre-
column derivatized with o-phthaldialdehyde (Geddes and Wood, 1984) and subsequently 
separated on a ZORBAX SB-C18 (4.6 × 250 mm, 5 μm) column from Agilent by use of a 
phosphate buffer (50 mM, pH = 5.9), a solution of methanol (98.75 %) and 
tetrahydrofurane (1.25 %) as eluents. The separated amino acids were detected with 
fluorescence and quantified by comparison to a standard curve derived from the standard 
solutions of amino acids which were run after every twelfth sample.
Quantification of monoamines was done by collaborators from another laboratory. See 
Paper 3 for details.
3.3 13C NMR Spectroscopy
A Bruker DRX-600 spectrometer or Bruker DRX-500 (BRUKER Analytik GmbH, 
Rheinstetten, Germany) was used to obtain proton decoupled 150.92 MHz 13C NMR 
spectra. For this procedure the samples were redissolved in 400 or 200 μL D2O 
containing ethylene glycol 0.1% as an internal standard. Scans were obtained with a 30o
pulse angle and 30 kHz spectral width with 64K data points. The acquisition time was 
1.08 s, the relaxation delay 2.5 or 0.5 s and the number of scans was typically 10 000.
The relevant peaks in the 13C and 1H NMR spectra were identified and integrated using 
XWINNMR software. The amounts of metabolites and 13C were quantified from the 
integrals of each relevant peak, using ethylene glycol as an internal standard. A 
correction factor for nOe and T1 was determined for each peak using the inverse gated 
decoupling experiment (Derome, 1987). The factor was applied to all spectra.
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3.4 1H NMR Spectroscopy
A Bruker DRX-600 spectrometer was used to obtain 1H NMR spectra with a sweep width 
of 12 kHz with 32K data points. The pulse angle was 90o, the acquisition time 1.36 s and 
the relaxation delay was 10 s. The number of scans was 400. Water suppression was set 
at the residual H2O resonance.
4 Results
4.1 Paper 1
Sprague-Dawley rats received either a single injection of MK-801 (0.5mg/kg) or saline 
i.p. together with [1-13C]glucose (543mg/kg) and [1,2-13C]acetate (504mg/kg). After 
decapitation the temporal lobe (TL) and the cingulate, retrosplenial and frontal cortices 
(FCR) were prepared and examined by HPLC, 1H NMRS and 13C NMRS. Hypofunction 
of the NMDA receptor induced similar changes in both brain areas investigated. 
However, the changes were most pronounced in TL. Generally, only labeling from
[1-13C]glucose was affected by MK-801. The only change in labeling from 
[1,2-13C]acetate was in an isotopomer of glutamine derived from the second turn of the 
TCA cycle. In FCR and TL amounts of both labeled and unlabeled glutamine were 
increased, whereas those of aspartate were decreased. The amount of lactate, formed 
from unlabeled glucose or other unlabeled substrates, was also increased in both areas. In 
TL, not in FCR, increased concentrations of glutamate, GABA, succinate, glutathione 
and inositol were detected together with increased labeling of GABA and succinate from 
[1-13C]glucose and glutamine from [1,2-13C]acetate. 13C enrichment was increased in 
succinate and decreased in glutamate. Whereas labeled and unlabeled glutamine was 
increased both in FCR and TL, this was only the case for unlabeled glutamate in TL.
4.2 Paper 2
Rats were given i.p. injections of MK-801 (0.1 mg/kg) or saline on 6 consecutive days, 
the last dose together with [1-13C]glucose and [1,2-13C]acetate. Analyses of extracts from 
FCR and TL were performed using 13C and 1H NMRS. Increases in amounts and labeling 
of glutamate and glutamine from [1-13C]glucose and [1,2-13C]acetate were confined to 
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TL. The amounts of [2-13C]aspartate, derived from [1-13C]glucose, and succinate were 
elevated in TL as well. 
4.3 Paper 3
Saline or MK-801 (0.5mg/kg) were injected i.p. every day for six days and 
hyperlocomotion and ataxia measured semi-quantitatively for half an hour after each 
injection. The last dose was given together with [1-13C]glucose (543mg/kg) and 
[1,2-13C]acetate (504mg/kg) followed by decapitation 20 minutes later. TL and FCR 
extracts were studied by HPLC, 13C and 1H NMRS. Five controls and three MK-801 
animals underwent cardiac perfusion. Hematoxilin-Eosin- and Nissl-stained histological 
slices from FCR, TL and hippocampus were examined by light microscopy and no 
morphological changes were found. Significant behavioral alterations such as head 
waving, hyperlocomotion, abducted hind limbs and ataxia were seen and exhibited 
considerable variability. MK-801 affected the FCR to a much greater extent than the 
temporal lobe with significant increases in the levels of glutathione, glutamate and 
taurine, but, at the same time, unchanged amounts of and turnover rates for dopamine, 
noradrenaline and serotonin in cortex. [4,5-13C]glutamate and [4,5-13C]glutamine, derived 
from [1,2-13C]acetate, were significantly decreased in FCR. Label from [1-13C]glucose 
was affected in the same brain region with decreases of [4-13C]glutamate, [2-13C]GABA 
and [4-13C]GABA, whereas in the temporal lobe both [1,2-13C]acetate- and 
[1-13C]glucose-derived metabolites remained unchanged. Glutamate cycling from 
[1-13C]glucose was enhanced in both brain areas investigated and an increase of the 
cycling ratio for 13C from [1,2-13C]acetate was found for glutamine in the FCR. 
Acetate/glucose utilization ratios of glutamate and glutamine were decreased in the FCR.
4.4 Paper 4
We examined potential disturbances in energy metabolism and interactions between 
neurons and glia in 15 week-old STOP KO, wild type and heterozygous mice. Animals 
received [1-13C]glucose and [1,2-13C]acetate, the preferential substrates of neurons and 
astrocytes, respectively. Extracts from the whole forebrain and midbrain excluding the 
brainstem and the cerebellum were analyzed by HPLC, 13C and 1H NMRS. Amounts and 
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4.4 Paper 4
We examined potential disturbances in energy metabolism and interactions between 
neurons and glia in 15 week-old STOP KO, wild type and heterozygous mice. Animals 
received [1-13C]glucose and [1,2-13C]acetate, the preferential substrates of neurons and 
astrocytes, respectively. Extracts from the whole forebrain and midbrain excluding the 
brainstem and the cerebellum were analyzed by HPLC, 13C and 1H NMRS. Amounts and 
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TL. The amounts of [2-13C]aspartate, derived from [1-13C]glucose, and succinate were 
elevated in TL as well. 
4.3 Paper 3
Saline or MK-801 (0.5mg/kg) were injected i.p. every day for six days and 
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injection. The last dose was given together with [1-13C]glucose (543mg/kg) and 
[1,2-13C]acetate (504mg/kg) followed by decapitation 20 minutes later. TL and FCR 
extracts were studied by HPLC, 13C and 1H NMRS. Five controls and three MK-801 
animals underwent cardiac perfusion. Hematoxilin-Eosin- and Nissl-stained histological 
slices from FCR, TL and hippocampus were examined by light microscopy and no 
morphological changes were found. Significant behavioral alterations such as head 
waving, hyperlocomotion, abducted hind limbs and ataxia were seen and exhibited 
considerable variability. MK-801 affected the FCR to a much greater extent than the 
temporal lobe with significant increases in the levels of glutathione, glutamate and 
taurine, but, at the same time, unchanged amounts of and turnover rates for dopamine, 
noradrenaline and serotonin in cortex. [4,5-13C]glutamate and [4,5-13C]glutamine, derived 
from [1,2-13C]acetate, were significantly decreased in FCR. Label from [1-13C]glucose 
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labeling of most metabolites were unchanged. However, glutamine concentration and 
amount of [4,5-13C]glutamine derived from [1,2-13C]acetate were significantly decreased 
by 17% and 18%, respectively, in STOP KO compared to wild type mice. The amount of 
[4-13C]glutamate was decreased in STOP KO and heterozygous mice compared to wild 
type. However, levels of [4-13C]glutamine were unchanged.
5 Discussion
Analyses of brain metabolites from MK-801-treated rats using 13C NMR spectroscopy in 
Paper 1-3 have substantially increased knowledge of impairments of neurotransmitter 
metabolism in NMDA receptor hypofunction. A single dose of 0.5 mg/kg, MK-801 
produced predominantly changes in the temporal lobe with increased total amounts of 
glutamate and glutamine and labeling from [1-13C]glucose (Paper 1). Similar changes 
were observed when MK-801 was administered repeatedly at 0.1 mg/kg for 6 consecutive 
days and all metabolic alterations were confined to the temporal lobe (Paper 2). However, 
changes were found in FCR when MK-801 was administered repeatedly  at 0.5 mg/kg 
(Paper 3) instead of 0.1 mg/kg repeatedly. In vivo NMR spectroscopy studies of patients 
with schizophrenia showed that first-episode schizophrenic patients have 
elevated glutamine levels in the medial prefrontal and the left anterior cingulate cortex 
(Bartha et al., 1997, Theberge et al., 2002), whereas decreased glutamine and glutamate 
levels were found in the anterior cingulate of patients with chronic schizophrenia 
(Theberge et al., 2003). The FCR in our studies includes both the medial prefrontal and 
the anterior cingulate cortex. Accordingly, repeated injections of high doses of MK-801 
cause similar alterations to those from first-episode patients. In paper 4, a decreased level 
of glutamine is reported in the cerebrum of STOP KO mice compared to wild type mice.
It appears that the 15-week-old STOP KO mice mimic chronic schizophrenia but not 
first-episode schizophrenia. Consequently, the STOP KO mice may be a good model for 
chronic schizophrenia and the model of repeated injections of high doses of MK-801 may 
be a good model for first-episode schizophrenia. 
As shown in Paper 1 and Paper 2, the total amounts of glutamine and glutamine labeled 
from [1-13C]glucose and hence  from neuronal metabolism were increased. Such an 
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increase could be due to the increased activity of glutamine synthetase. However, no 
changes were observed in [4,5-13C]glutamine and [4,5-13C]glutamate from [1,2-
13C]acetate, which accordingly demonstrated the unperturbed metabolic flux from 
astrocytes to neurons. These observations both indicate that not all GS was affected by 
MK-801 and reveals s compartmentation of glutamine metabolism, where glutamine 
labeled from neuronal glutamate ([4-13C]glutamate) is handled in a different compartment 
than glutamine from astrocytic glutamate.
As it comes to Paper 4, decreased levels of both total glutamine and labeled 
[4,5-13C]glutamine were reported in the cerebrum of STOP KO mice. In contrast to the 
MK-801 experiments, this indicates a decreased glutamine synthesis by glutamine 
synthetase in the STOP KO mice. Interestingly, in the fourth study, there were no
changes found in the [4-13C]glutamine levels and , as a result,   a compartmentation of 
glutamine metabolism in the STOP KO mouse  also has to be proposed. A 
hypoglutamatergic state is present in both the MK-801 model and in the STOP KO 
mouse: In MK-801 injected rats, the state was caused by the MK-801 blocking the 
NMDA receptor, while in the STOP KO mouse, a reduction of the glutamatergic synaptic 
vesicle pool shown in some brain areas (Andrieux et al., 2002, Andrieux et al., 2006).
Both these cases would cause a decreased influx of Ca2+ into the postsynaptic neuron 
through the NMDA receptor ion channel. Ca2+ entry into the postsynaptic neuron 
activates NO-synthase (NOS) through a second messenger system involving calmodulin 
(Kosenko et al., 2003). Nitric Oxide (NO) synthesized in the postsynaptic neuron does 
not only affect the post- and presynaptic neuron, but also shows effects in the nearby 
astrocyte. One of the effects is a tonic inhibition of GS (Kosenko et al., 2003). Reduced 
influx of Ca2+ can then, through disinhibition of astrocytic GS, cause increased glutamine 
production in the astrocyte. This hypothesis is able to explain the compartmentation of 
glutamine metabolism in both the MK-801 single dose model and in the STOP KO 
mouse. In the STOP KO mice, GS activity in general is decreased, There is however an 
increased GS activity caused by reduced activation of postsynaptic NMDA receptors in 
the parts of the astrocytes in absolute vicinity of the postsynaptic spines. In the MK-801
treated rats (single injection with high dose), the GS activity in general is normal, but in 
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the synaptic parts of the astrocyte, it is increased (See Figure 4). The finding that the 
activity of glutamine synthetase is decreased in brains of schizophrenic patients 
(Burbaeva et al., 2003) further strengthens the assumption that the glutamate-glutamine 
cycle is disrupted in schizophrenia. It also gives  support to the STOP KO mouse as an 
animal model of schizophrenia.
Figure 4: Schematic representation of the glutamate-glutamine cycle related interactions of an 
astrocyte with a pre- and postsynaptic neuron. (1) [1,2-13C]Acetate is taken up by astrocytes, but 
not by neurons. Through the tricarboxylic cycle (TCA), [1,2-13C]acetatyl CoA is converted to 
[4,5-13C]glutamate. Glutamine synthetase (GS) converts [4,5-13C]glutamate to [4,5-13C]glutamine. 
(2) Glucose is mostly taken up by neurons. [1-13C]glucose is after several steps converted to 
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[4-13C]glutamate. (3) Synaptic glutamate release. (4) NMDA receptors are activated by synaptic 
glutamate and allow influx of Ca2+ into the postsynaptic dendrite. Ca2+ activates the enzyme nitric 
oxide synthase (NOS). (5) NO may diffuse into the astrocyte where it normally inhibits GS. 
Reduced activation of NMDA receptors by glutamate leads to reduced NO production resulting in 
less inhibition of GS. This will only be the case in the part of the astrocyte close to the synapse. 
Abbreviations: 4,5-Gln, [4,5-13C]glutamine; 4,5-Glu, [4,5-13C]glutamate; 4-Gln, [4-13C]glutamine; 
4-Glu, [4-13C]glutamate; GS, glutamine synthetase; NO, nitric oxide; NOS, nitric oxide synthase; 
Pyr, pyruvate; TCA, tricarboxylic acid cycle.
Why do different doses of MK-801 impair brain metabolism in the different brain 
regions? Possibly, the clue to this mystery lies in the diversity of neuronal pathways. 
Thus, blocking the release of glutamate from glutamatergic neurons which act on 
inhibitory GABAergic interneurons, might be neurotoxic.yThe reason for that might be 
the indirect increase of glutamate release at a second glutamatergic neuron behind the 
interneuron (Farber et al., 1995). In contrast, NMDA receptor blockade, at the second 
glutamatergic neuron at the end of this chain might have a neuroprotective effect. 
Whereas a single high dose and repeated low doses of MK-801 evoked metabolic 
changes in the TL, repeated high doses had almost no effects on the temporal lobe, but 
led to significant impairment in the FCR. It is very noteworthy in this context that MK-
801, when directly injected into the FCR, does not induce the neurotoxic reactions seen 
with comparable systemic doses (Farber et al., 2002). Thus, NMDA receptor blockade is 
probably required at one or more sites outside the FCR to generate these neurotoxic 
effects. In other words, we are probably dealing with polysynaptic network disturbances. 
Different doses of MK-801 may cause the same local reactions in the FCR, but may have 
different outcome in non-FCR areas. Thereby high doses of MK-801 will probably 
change polysynaptic chains in such a way that metabolism will mostly be impaired in 
FCR. Low doses of MK-801, on the other hand, affect other polysynaptic chains and 
provoke alterations in the temporal lobe. One may argue that the relevant polysynaptic 
changes have to be sensitized, since only repeated doses, but not a single dose, of 0.5 
mg/kg MK-801 lead to alterations in the FCR. 
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6 Conclusions
Repeated injections of the NMDA receptor antagonist MK-801 (0,5 mg/kg body weight) 
in rodents may be a good model of first-episode schizophrenia, whereas the STOP KO 
mouse model show similarities to, and may be a good model of chronic schizophrenia. 
A single high dose injection of MK-801 is an important tool to get the insights into 
hypoglutamatergia per se. Both NMDA receptor hypofunction and loss of microtubule 
stability seem to disrupt the glutamate-glutamine cycle. It can be stated that astrocytic-
neuronal interactions are probably underestimated in schizophrenia research. Future 
drugs, designed to stabilize astrocytic-neuronal interactions, may have potent 
antipsychotic properties. 
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Abstract
Glutamate-induced neurotoxicity plays an important role in neurological and psychiatric diseases. Thus, much attention has been given to the
potential neuroprotective role of glutamate receptor antagonists, especially to those acting on the N-methyl-D-aspartate (NMDA) subtype.
However, in addition to their neuroprotective potential, these compounds have also neurotoxic and psychotogenic properties. In the present study
we used repeated injections of MK801 to examine if this non-competitive NMDA receptor antagonist could be used to produce schizophrenia-like
alterations in behavior and brain metabolism in animals. Rats were given injections of MK801 (0.1 mg/kg) on six consecutive days, the last dose
together with [1-13C]glucose and [1,2-13C]acetate, to probe neuronal and astrocytic metabolism, respectively. Analyses of extracts from parts of the
frontal cortex plus cingulate and retrosplenial cortices and temporal lobes were performed using 13C and 1H magnetic resonance spectroscopy.
Changes in glutamate and glutamine were restricted to the temporal lobe, in which amounts and labeling from [1-13C]glucose and [1,2-13C]acetate
were increased compared to control. Locomotor activity was slightly higher in rats treated with MK801 compared to untreated animals. Metabolic
changes did not resemble the alterations occurring in schizophrenia and those after repeated high dose (0.5 mg/kg) [Kondziella, D., Brenner, E.,
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1. Introduction
In order to establish new treatments, N-methyl-D-aspartate
(NMDA) and other glutamate receptor antagonists have been
tested clinically in many CNS disorders (Bensimon et al., 1994;
Bullock et al., 1999; Davis et al., 2000). The principal
therapeutic strategy is to reduce the neurotoxicity of excessive
glutamate release. Some authors reported on the neuroprotec-
tive potential of glutamate antagonists (for review see
Himmelseher and Durieux, 2005) some on lack of effect
(Muir and Lees, 2003) and some revealed additional neurotoxic
potential of glutamate/NMDA antagonism (Olney and Farber,
1994; Farber et al., 1996, 1998, 2002; Kim et al., 1999). Results
of clinical studies using NMDA antagonism have been quite
disappointing, although with increasing knowledge about the
complexity of NMDA receptor subtypes this might change in
the future. For a review on ‘‘the enormous potential of NMDA
receptor antagonists’’ see Smith (2003).
NMDA antagonists have found use as tools to produce
schizophrenia-like symptoms in animals. Several transmitter
systems have been implicated in the pathogenesis of schizo-
phrenia and combined dysfunction of the glutamate and
dopamine systems has been suggested (Javitt and Zukin, 1991;
Olney and Farber, 1995; Carlsson and Carlsson, 1999; Flores
and Coyle, 2003). Disturbed glutamatergic neurotransmission
is especially relevant in patients with signiﬁcant negative
symptoms and cognitive impairment (Goff and Coyle, 2001;
Tsai and Coyle, 2002; Harrison and Weinberger, 2005).
Furthermore, lower glutamate levels in the cerebrospinal ﬂuid
of schizophrenia patients have been reported as well as changes
in the metabotropic and the ionotropic glutamate receptors
in postmortem brain tissue (reviewed by Tamminga, 1998).
www.elsevier.com/locate/neuint
Neurochemistry International 48 (2006) 541–546
* Corresponding author at: Department of Neuroscience, Faculty of Medi-
cine, NTNU, Olav Kyrres gate. 3, N-7489 Trondheim, Norway.
Tel.: +47 73590492; fax: +47 73598655.
E-mail address: Ursula.Sonnewald@ntnu.no (U. Sonnewald).
0197-0186/$ – see front matter # 2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuint.2005.11.019
Repeated injection of MK801: An animal model of schizophrenia?
Elvar M. Eyjolfsson a, Eiliv Brenner a, Daniel Kondziella a,b, Ursula Sonnewald a,*
aDepartment of Neuroscience, Norwegian University of Science and Technology (NTNU), N-7489 Trondheim, Norway
bDepartment of Neurology, University Hospital Sahlgrenska Gothenburg, SE-41345 Goteborg, Sweden
Received 17 October 2005; accepted 2 November 2005
Available online 3 March 2006
Abstract
Glutamate-induced neurotoxicity plays an important role in neurological and psychiatric diseases. Thus, much attention has been given to the
potential neuroprotective role of glutamate receptor antagonists, especially to those acting on the N-methyl-D-aspartate (NMDA) subtype.
However, in addition to their neuroprotective potential, these compounds have also neurotoxic and psychotogenic properties. In the present study
we used repeated injections of MK801 to examine if this non-competitive NMDA receptor antagonist could be used to produce schizophrenia-like
alterations in behavior and brain metabolism in animals. Rats were given injections of MK801 (0.1 mg/kg) on six consecutive days, the last dose
together with [1-13C]glucose and [1,2-13C]acetate, to probe neuronal and astrocytic metabolism, respectively. Analyses of extracts from parts of the
frontal cortex plus cingulate and retrosplenial cortices and temporal lobes were performed using 13C and 1H magnetic resonance spectroscopy.
Changes in glutamate and glutamine were restricted to the temporal lobe, in which amounts and labeling from [1-13C]glucose and [1,2-13C]acetate
were increased compared to control. Locomotor activity was slightly higher in rats treated with MK801 compared to untreated animals. Metabolic
changes did not resemble the alterations occurring in schizophrenia and those after repeated high dose (0.5 mg/kg) [Kondziella, D., Brenner, E.,
Eyjolfsson, E.M., Markinhuhta, K.R., Carlsson, M., Sonnewald, U., 2005. Glial–neuronal interactions are impaired in the schizophrenia model of
repeated MK801 exposure. Neuropsychopharmacology, Epub ahead of print] but rather those caused by MK801 seen after a single high dose
(0.5 mg/kg) [Brenner, E., Kondziella, D., Haberg, A., Sonnewald, U., 2005. Impaired glutamine metabolism in NMDA receptor hypofunction
induced by MK801. J. Neurochem. 94, 1594–1603.].
# 2006 Elsevier Ltd. All rights reserved.
Keywords: [1-13C]glucose; [1,2-13C]acetate; MK801; NMDA; GABA; Glutamate; Metabolism; NMR spectroscopy
1. Introduction
In order to establish new treatments, N-methyl-D-aspartate
(NMDA) and other glutamate receptor antagonists have been
tested clinically in many CNS disorders (Bensimon et al., 1994;
Bullock et al., 1999; Davis et al., 2000). The principal
therapeutic strategy is to reduce the neurotoxicity of excessive
glutamate release. Some authors reported on the neuroprotec-
tive potential of glutamate antagonists (for review see
Himmelseher and Durieux, 2005) some on lack of effect
(Muir and Lees, 2003) and some revealed additional neurotoxic
potential of glutamate/NMDA antagonism (Olney and Farber,
1994; Farber et al., 1996, 1998, 2002; Kim et al., 1999). Results
of clinical studies using NMDA antagonism have been quite
disappointing, although with increasing knowledge about the
complexity of NMDA receptor subtypes this might change in
the future. For a review on ‘‘the enormous potential of NMDA
receptor antagonists’’ see Smith (2003).
NMDA antagonists have found use as tools to produce
schizophrenia-like symptoms in animals. Several transmitter
systems have been implicated in the pathogenesis of schizo-
phrenia and combined dysfunction of the glutamate and
dopamine systems has been suggested (Javitt and Zukin, 1991;
Olney and Farber, 1995; Carlsson and Carlsson, 1999; Flores
and Coyle, 2003). Disturbed glutamatergic neurotransmission
is especially relevant in patients with signiﬁcant negative
symptoms and cognitive impairment (Goff and Coyle, 2001;
Tsai and Coyle, 2002; Harrison and Weinberger, 2005).
Furthermore, lower glutamate levels in the cerebrospinal ﬂuid
of schizophrenia patients have been reported as well as changes
in the metabotropic and the ionotropic glutamate receptors
in postmortem brain tissue (reviewed by Tamminga, 1998).
www.elsevier.com/locate/neuint
Neurochemistry International 48 (2006) 541–546
* Corresponding author at: Department of Neuroscience, Faculty of Medi-
cine, NTNU, Olav Kyrres gate. 3, N-7489 Trondheim, Norway.
Tel.: +47 73590492; fax: +47 73598655.
E-mail address: Ursula.Sonnewald@ntnu.no (U. Sonnewald).
0197-0186/$ – see front matter # 2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuint.2005.11.019
Repeated injection of MK801: An animal model of schizophrenia?
Elvar M. Eyjolfsson a, Eiliv Brenner a, Daniel Kondziella a,b, Ursula Sonnewald a,*
aDepartment of Neuroscience, Norwegian University of Science and Technology (NTNU), N-7489 Trondheim, Norway
bDepartment of Neurology, University Hospital Sahlgrenska Gothenburg, SE-41345 Goteborg, Sweden
Received 17 October 2005; accepted 2 November 2005
Available online 3 March 2006
Abstract
Glutamate-induced neurotoxicity plays an important role in neurological and psychiatric diseases. Thus, much attention has been given to the
potential neuroprotective role of glutamate receptor antagonists, especially to those acting on the N-methyl-D-aspartate (NMDA) subtype.
However, in addition to their neuroprotective potential, these compounds have also neurotoxic and psychotogenic properties. In the present study
we used repeated injections of MK801 to examine if this non-competitive NMDA receptor antagonist could be used to produce schizophrenia-like
alterations in behavior and brain metabolism in animals. Rats were given injections of MK801 (0.1 mg/kg) on six consecutive days, the last dose
together with [1-13C]glucose and [1,2-13C]acetate, to probe neuronal and astrocytic metabolism, respectively. Analyses of extracts from parts of the
frontal cortex plus cingulate and retrosplenial cortices and temporal lobes were performed using 13C and 1H magnetic resonance spectroscopy.
Changes in glutamate and glutamine were restricted to the temporal lobe, in which amounts and labeling from [1-13C]glucose and [1,2-13C]acetate
were increased compared to control. Locomotor activity was slightly higher in rats treated with MK801 compared to untreated animals. Metabolic
changes did not resemble the alterations occurring in schizophrenia and those after repeated high dose (0.5 mg/kg) [Kondziella, D., Brenner, E.,
Eyjolfsson, E.M., Markinhuhta, K.R., Carlsson, M., Sonnewald, U., 2005. Glial–neuronal interactions are impaired in the schizophrenia model of
repeated MK801 exposure. Neuropsychopharmacology, Epub ahead of print] but rather those caused by MK801 seen after a single high dose
(0.5 mg/kg) [Brenner, E., Kondziella, D., Haberg, A., Sonnewald, U., 2005. Impaired glutamine metabolism in NMDA receptor hypofunction
induced by MK801. J. Neurochem. 94, 1594–1603.].
# 2006 Elsevier Ltd. All rights reserved.
Keywords: [1-13C]glucose; [1,2-13C]acetate; MK801; NMDA; GABA; Glutamate; Metabolism; NMR spectroscopy
1. Introduction
In order to establish new treatments, N-methyl-D-aspartate
(NMDA) and other glutamate receptor antagonists have been
tested clinically in many CNS disorders (Bensimon et al., 1994;
Bullock et al., 1999; Davis et al., 2000). The principal
therapeutic strategy is to reduce the neurotoxicity of excessive
glutamate release. Some authors reported on the neuroprotec-
tive potential of glutamate antagonists (for review see
Himmelseher and Durieux, 2005) some on lack of effect
(Muir and Lees, 2003) and some revealed additional neurotoxic
potential of glutamate/NMDA antagonism (Olney and Farber,
1994; Farber et al., 1996, 1998, 2002; Kim et al., 1999). Results
of clinical studies using NMDA antagonism have been quite
disappointing, although with increasing knowledge about the
complexity of NMDA receptor subtypes this might change in
the future. For a review on ‘‘the enormous potential of NMDA
receptor antagonists’’ see Smith (2003).
NMDA antagonists have found use as tools to produce
schizophrenia-like symptoms in animals. Several transmitter
systems have been implicated in the pathogenesis of schizo-
phrenia and combined dysfunction of the glutamate and
dopamine systems has been suggested (Javitt and Zukin, 1991;
Olney and Farber, 1995; Carlsson and Carlsson, 1999; Flores
and Coyle, 2003). Disturbed glutamatergic neurotransmission
is especially relevant in patients with signiﬁcant negative
symptoms and cognitive impairment (Goff and Coyle, 2001;
Tsai and Coyle, 2002; Harrison and Weinberger, 2005).
Furthermore, lower glutamate levels in the cerebrospinal ﬂuid
of schizophrenia patients have been reported as well as changes
in the metabotropic and the ionotropic glutamate receptors
in postmortem brain tissue (reviewed by Tamminga, 1998).
www.elsevier.com/locate/neuint
Neurochemistry International 48 (2006) 541–546
* Corresponding author at: Department of Neuroscience, Faculty of Medi-
cine, NTNU, Olav Kyrres gate. 3, N-7489 Trondheim, Norway.
Tel.: +47 73590492; fax: +47 73598655.
E-mail address: Ursula.Sonnewald@ntnu.no (U. Sonnewald).
0197-0186/$ – see front matter # 2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuint.2005.11.019
Repeated injection of MK801: An animal model of schizophrenia?
Elvar M. Eyjolfsson a, Eiliv Brenner a, Daniel Kondziella a,b, Ursula Sonnewald a,*
aDepartment of Neuroscience, Norwegian University of Science and Technology (NTNU), N-7489 Trondheim, Norway
bDepartment of Neurology, University Hospital Sahlgrenska Gothenburg, SE-41345 Goteborg, Sweden
Received 17 October 2005; accepted 2 November 2005
Available online 3 March 2006
Abstract
Glutamate-induced neurotoxicity plays an important role in neurological and psychiatric diseases. Thus, much attention has been given to the
potential neuroprotective role of glutamate receptor antagonists, especially to those acting on the N-methyl-D-aspartate (NMDA) subtype.
However, in addition to their neuroprotective potential, these compounds have also neurotoxic and psychotogenic properties. In the present study
we used repeated injections of MK801 to examine if this non-competitive NMDA receptor antagonist could be used to produce schizophrenia-like
alterations in behavior and brain metabolism in animals. Rats were given injections of MK801 (0.1 mg/kg) on six consecutive days, the last dose
together with [1-13C]glucose and [1,2-13C]acetate, to probe neuronal and astrocytic metabolism, respectively. Analyses of extracts from parts of the
frontal cortex plus cingulate and retrosplenial cortices and temporal lobes were performed using 13C and 1H magnetic resonance spectroscopy.
Changes in glutamate and glutamine were restricted to the temporal lobe, in which amounts and labeling from [1-13C]glucose and [1,2-13C]acetate
were increased compared to control. Locomotor activity was slightly higher in rats treated with MK801 compared to untreated animals. Metabolic
changes did not resemble the alterations occurring in schizophrenia and those after repeated high dose (0.5 mg/kg) [Kondziella, D., Brenner, E.,
Eyjolfsson, E.M., Markinhuhta, K.R., Carlsson, M., Sonnewald, U., 2005. Glial–neuronal interactions are impaired in the schizophrenia model of
repeated MK801 exposure. Neuropsychopharmacology, Epub ahead of print] but rather those caused by MK801 seen after a single high dose
(0.5 mg/kg) [Brenner, E., Kondziella, D., Haberg, A., Sonnewald, U., 2005. Impaired glutamine metabolism in NMDA receptor hypofunction
induced by MK801. J. Neurochem. 94, 1594–1603.].
# 2006 Elsevier Ltd. All rights reserved.
Keywords: [1-13C]glucose; [1,2-13C]acetate; MK801; NMDA; GABA; Glutamate; Metabolism; NMR spectroscopy
1. Introduction
In order to establish new treatments, N-methyl-D-aspartate
(NMDA) and other glutamate receptor antagonists have been
tested clinically in many CNS disorders (Bensimon et al., 1994;
Bullock et al., 1999; Davis et al., 2000). The principal
therapeutic strategy is to reduce the neurotoxicity of excessive
glutamate release. Some authors reported on the neuroprotec-
tive potential of glutamate antagonists (for review see
Himmelseher and Durieux, 2005) some on lack of effect
(Muir and Lees, 2003) and some revealed additional neurotoxic
potential of glutamate/NMDA antagonism (Olney and Farber,
1994; Farber et al., 1996, 1998, 2002; Kim et al., 1999). Results
of clinical studies using NMDA antagonism have been quite
disappointing, although with increasing knowledge about the
complexity of NMDA receptor subtypes this might change in
the future. For a review on ‘‘the enormous potential of NMDA
receptor antagonists’’ see Smith (2003).
NMDA antagonists have found use as tools to produce
schizophrenia-like symptoms in animals. Several transmitter
systems have been implicated in the pathogenesis of schizo-
phrenia and combined dysfunction of the glutamate and
dopamine systems has been suggested (Javitt and Zukin, 1991;
Olney and Farber, 1995; Carlsson and Carlsson, 1999; Flores
and Coyle, 2003). Disturbed glutamatergic neurotransmission
is especially relevant in patients with signiﬁcant negative
symptoms and cognitive impairment (Goff and Coyle, 2001;
Tsai and Coyle, 2002; Harrison and Weinberger, 2005).
Furthermore, lower glutamate levels in the cerebrospinal ﬂuid
of schizophrenia patients have been reported as well as changes
in the metabotropic and the ionotropic glutamate receptors
in postmortem brain tissue (reviewed by Tamminga, 1998).
www.elsevier.com/locate/neuint
Neurochemistry International 48 (2006) 541–546
* Corresponding author at: Department of Neuroscience, Faculty of Medi-
cine, NTNU, Olav Kyrres gate. 3, N-7489 Trondheim, Norway.
Tel.: +47 73590492; fax: +47 73598655.
E-mail address: Ursula.Sonnewald@ntnu.no (U. Sonnewald).
0197-0186/$ – see front matter # 2006 Elsevier Ltd. All rights reserved.
doi:10.1016/j.neuint.2005.11.019
In addition to the prefrontal cortex, the bulk of the data
concerns the hippocampus (Heckers and Konradi, 2002;
Harrison et al., 2003). Interestingly, all the known susceptibility
genes for schizophrenia act on glutamatergic synaptic
transmission (Harrison and Weinberger, 2005). However,
reduced GABA synthesis has also been reported in schizo-
phrenic patients (Lewis et al., 2005).
Animal models can help to better understand and ﬁnd ways
to cure human diseases.We have investigated the use ofMK801
as a model of schizophrenia using different protocols (Brenner
et al., 2005; Kondziella et al., 2005). Neurometabolite
concentrations and turnover were assessed by high ﬁeld 13C
and 1H NMR spectroscopy and analyzed with special
emphasize on glial–neuronal interactions. Due to the close
connection of astrocyte metabolism and the synthesis of
glutamate and GABA in neurons, there are good reasons to
hypothesize an astrocytic role in the pathophysiology of
schizophrenia and glutamate dysfunction (Kondziella et al.,
2005). Earlier we have injected a single, relatively high dose of
MK801 (0.5 mg/kg) and observed distinct behavioral abnorm-
alities and increased levels of glutamate, glutamine and GABA
combined with increased labeling of these amino acids mostly
in temporal lobe (Brenner et al., 2005). After repeated
injections of the same dose, increased levels of glutamate
were found in the frontal cortex plus cingulate and retrosplenial
cortices (FCR) but not in temporal lobe (Kondziella et al.,
2005). To determine whether also a lower dose would produce
schizophrenia-like alterations, rats were injected with 0.1 mg/
kg MK801 every day for six consecutive days. Metabolite
composition was analyzed by 13C and 1H NMR spectroscopy.
2. Materials and methods
2.1. Materials
Male Sprague Dawley rats (with an average weight of 250 g) were obtained
from Mo¨llegaard Breeding centre, Copenhagen, Denmark. Animals were
housed in individual cages at a constant temperature of 22 8C with a 12 h
light/dark cycle and a humidity of 60%. Animals had free access to food and
water. [1-13C]glucose, [1,2-13C]acetate and D2O (99.9%) were purchased from
Cambridge Isotopes Laboratories (Woburn, MA, USA); ethylene glycol from
Merck (Darmstad, Germany); MK801 (Diozocilpine; [5R,10S]-[+]-5-methyl-
10,11-dihydro-5H-dibenzo[a,d]cyclopheten-5,10-imine), from Sigma–Aldrich
(St. Louis, MO, USA). All other chemicals were of the purest grade available
from local commercial sources.
2.2. Dosing and experimental design
The experimental design was approved by the Norwegian Animal Research
Authorities Welfare and the local ethics committee. Animals were injected with
saline or MK801 (0.1 mg/kg body weight) intraperitoneally every day for six
days. The last dose of saline or MK801 was given together with [1-13C]glucose
(543 mg/kg, 0.3 M solution) and [1,2-13C]acetate (504 mg/kg, 0.6 M solution).
Twenty minutes later animals were decapitated, heads were snap frozen in
liquid nitrogen and stored at 80 8C. Brains were removed, and two areas of
each hemisphere were dissected. The ﬁrst area included the cingulate, the
retrosplenial and parts of the frontal cortices (FCR). The second area, the
temporal lobe, was dissected by a horizontal cut from the most lateral point of
the hemisphere extending approximately 3 mm medially and a second sagittal
cut extending ventrally through the whole brain. The resulting sample consisted
of the temporal cortex, piriform cortex, entorhinal cortex, amygdala and parts of
the hippocampus. The dissection was performed on ice while the brains were
still frozen. Thereafter, brain tissue was homogenized in 7% perchloric acid and
centrifuged at 4000  g for 5 min. The procedure was repeated, the super-
natants pooled and neutralized with 1 M KOH followed by centrifugation and
lyophilization.
2.3. Evaluation of behavior
Cages were divided into four equally large areas by imaginary lines. After
each drug administration locomotor activity was scored by counting how often
the animals crossed the lines during a speciﬁc time interval.
2.4. 13C NMR spectroscopy and 1H NMR spectroscopy
Samples were dissolved in 200 ml D2O (deuterated water) containing
ethylene glycol 0.1% as an internal standard.
Proton decoupled 13C NMR spectra were obtained using a BRUKER DRX-
600 spectrometer (BRUKER Analytik GmbH, Rheinstetten, Germany). Scans
were accumulated with a 308 pulse angle and 30 kHz spectral width with 64 K
data points. The number of scans was 10,000. The acquisition time was 1.08 s,
the relaxation delay 0.5 s. Factors for the nuclear Overhauser and relaxation
effects were applied to all spectra.
1H NMR spectra was obtained using the same spectrometer. Scans were
accumulated with a pulse angle of 908 and a spectral width with 32 K data
points. The number of scans was 400. Acquisition time was 1.36 s and
relaxation delay was 10 s. Water suppression was achieved by applying a
low-power presaturation pulse at the water frequency.
2.5. Data analysis
The amounts of 13C and 1H in the different metabolites were quantiﬁed from
integrals of the relevant peaks obtained fromNMRspectrawith ethylene glycol as
an internal standard. Some spectras were not included in the analysis due to
methodological error. All results are given as mean standard deviation. Statis-
tics were performed using Student’s t-test, p < 0.05 was regarded as signiﬁcant.
3. Results
Repeated low dose injections of MK801 altered the behavior
of some animals. Locomotor activity was slightly increased in
3–4 animals at any given time point compared to control
(results not shown). Successive injections did not lead to
increased activity of the individual animal.
A typical 1H NMR spectrum is depicted in Fig. 1A, whereas
Fig. 1B shows a 13C NMR spectrum from an extract of temporal
lobe from a MK801 injected rat. 13C labeled amino acids and
other small molecules derived from [1-13C]glucose or
[1,2-13C]acetate are clearly detected. In order to interpret the
13C NMR spectra it is necessary to analyze the metabolic
pathways for [1-13C]glucose (Fig. 2A) and [1,2-13C]acetate
(Fig. 2B).
When [1-13C]glucose and [1,2-13C]acetate are administered
simultaneously, metabolic interactions between astrocytes and
neurons can be studied in the same animal. This is due to the
fact that acetate is exclusively taken up by astrocytes, while the
major part of acetyl-CoA derived from glucose is used in
neurons. Label from [1-13C]glucose and thus neuronal
metabolism can be quantiﬁed by analyzing the singlet peaks
in the spectrum. In contrast, the doublets seen in the spectra are
mainly derived from [1,2-13C]acetate and thus astrocytic
metabolism. In neurons [1-13C]glucose is converted to
[3-13C]pyruvate which can be transformed to [3-13C]lactate
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genes for schizophrenia act on glutamatergic synaptic
transmission (Harrison and Weinberger, 2005). However,
reduced GABA synthesis has also been reported in schizo-
phrenic patients (Lewis et al., 2005).
Animal models can help to better understand and ﬁnd ways
to cure human diseases.We have investigated the use ofMK801
as a model of schizophrenia using different protocols (Brenner
et al., 2005; Kondziella et al., 2005). Neurometabolite
concentrations and turnover were assessed by high ﬁeld 13C
and 1H NMR spectroscopy and analyzed with special
emphasize on glial–neuronal interactions. Due to the close
connection of astrocyte metabolism and the synthesis of
glutamate and GABA in neurons, there are good reasons to
hypothesize an astrocytic role in the pathophysiology of
schizophrenia and glutamate dysfunction (Kondziella et al.,
2005). Earlier we have injected a single, relatively high dose of
MK801 (0.5 mg/kg) and observed distinct behavioral abnorm-
alities and increased levels of glutamate, glutamine and GABA
combined with increased labeling of these amino acids mostly
in temporal lobe (Brenner et al., 2005). After repeated
injections of the same dose, increased levels of glutamate
were found in the frontal cortex plus cingulate and retrosplenial
cortices (FCR) but not in temporal lobe (Kondziella et al.,
2005). To determine whether also a lower dose would produce
schizophrenia-like alterations, rats were injected with 0.1 mg/
kg MK801 every day for six consecutive days. Metabolite
composition was analyzed by 13C and 1H NMR spectroscopy.
2. Materials and methods
2.1. Materials
Male Sprague Dawley rats (with an average weight of 250 g) were obtained
from Mo¨llegaard Breeding centre, Copenhagen, Denmark. Animals were
housed in individual cages at a constant temperature of 22 8C with a 12 h
light/dark cycle and a humidity of 60%. Animals had free access to food and
water. [1-13C]glucose, [1,2-13C]acetate and D2O (99.9%) were purchased from
Cambridge Isotopes Laboratories (Woburn, MA, USA); ethylene glycol from
Merck (Darmstad, Germany); MK801 (Diozocilpine; [5R,10S]-[+]-5-methyl-
10,11-dihydro-5H-dibenzo[a,d]cyclopheten-5,10-imine), from Sigma–Aldrich
(St. Louis, MO, USA). All other chemicals were of the purest grade available
from local commercial sources.
2.2. Dosing and experimental design
The experimental design was approved by the Norwegian Animal Research
Authorities Welfare and the local ethics committee. Animals were injected with
saline or MK801 (0.1 mg/kg body weight) intraperitoneally every day for six
days. The last dose of saline or MK801 was given together with [1-13C]glucose
(543 mg/kg, 0.3 M solution) and [1,2-13C]acetate (504 mg/kg, 0.6 M solution).
Twenty minutes later animals were decapitated, heads were snap frozen in
liquid nitrogen and stored at 80 8C. Brains were removed, and two areas of
each hemisphere were dissected. The ﬁrst area included the cingulate, the
retrosplenial and parts of the frontal cortices (FCR). The second area, the
temporal lobe, was dissected by a horizontal cut from the most lateral point of
the hemisphere extending approximately 3 mm medially and a second sagittal
cut extending ventrally through the whole brain. The resulting sample consisted
of the temporal cortex, piriform cortex, entorhinal cortex, amygdala and parts of
the hippocampus. The dissection was performed on ice while the brains were
still frozen. Thereafter, brain tissue was homogenized in 7% perchloric acid and
centrifuged at 4000  g for 5 min. The procedure was repeated, the super-
natants pooled and neutralized with 1 M KOH followed by centrifugation and
lyophilization.
2.3. Evaluation of behavior
Cages were divided into four equally large areas by imaginary lines. After
each drug administration locomotor activity was scored by counting how often
the animals crossed the lines during a speciﬁc time interval.
2.4. 13C NMR spectroscopy and 1H NMR spectroscopy
Samples were dissolved in 200 ml D2O (deuterated water) containing
ethylene glycol 0.1% as an internal standard.
Proton decoupled 13C NMR spectra were obtained using a BRUKER DRX-
600 spectrometer (BRUKER Analytik GmbH, Rheinstetten, Germany). Scans
were accumulated with a 308 pulse angle and 30 kHz spectral width with 64 K
data points. The number of scans was 10,000. The acquisition time was 1.08 s,
the relaxation delay 0.5 s. Factors for the nuclear Overhauser and relaxation
effects were applied to all spectra.
1H NMR spectra was obtained using the same spectrometer. Scans were
accumulated with a pulse angle of 908 and a spectral width with 32 K data
points. The number of scans was 400. Acquisition time was 1.36 s and
relaxation delay was 10 s. Water suppression was achieved by applying a
low-power presaturation pulse at the water frequency.
2.5. Data analysis
The amounts of 13C and 1H in the different metabolites were quantiﬁed from
integrals of the relevant peaks obtained fromNMRspectrawith ethylene glycol as
an internal standard. Some spectras were not included in the analysis due to
methodological error. All results are given as mean standard deviation. Statis-
tics were performed using Student’s t-test, p < 0.05 was regarded as signiﬁcant.
3. Results
Repeated low dose injections of MK801 altered the behavior
of some animals. Locomotor activity was slightly increased in
3–4 animals at any given time point compared to control
(results not shown). Successive injections did not lead to
increased activity of the individual animal.
A typical 1H NMR spectrum is depicted in Fig. 1A, whereas
Fig. 1B shows a 13C NMR spectrum from an extract of temporal
lobe from a MK801 injected rat. 13C labeled amino acids and
other small molecules derived from [1-13C]glucose or
[1,2-13C]acetate are clearly detected. In order to interpret the
13C NMR spectra it is necessary to analyze the metabolic
pathways for [1-13C]glucose (Fig. 2A) and [1,2-13C]acetate
(Fig. 2B).
When [1-13C]glucose and [1,2-13C]acetate are administered
simultaneously, metabolic interactions between astrocytes and
neurons can be studied in the same animal. This is due to the
fact that acetate is exclusively taken up by astrocytes, while the
major part of acetyl-CoA derived from glucose is used in
neurons. Label from [1-13C]glucose and thus neuronal
metabolism can be quantiﬁed by analyzing the singlet peaks
in the spectrum. In contrast, the doublets seen in the spectra are
mainly derived from [1,2-13C]acetate and thus astrocytic
metabolism. In neurons [1-13C]glucose is converted to
[3-13C]pyruvate which can be transformed to [3-13C]lactate
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or [3-13C]alanine or enter the TCA cycle as labeled
[2-13C]acetyl-CoA. The latter will lead to formation of
[4-13C]glutamate, [4-13C]glutamine and [2-13C]GABA. In
addition, in astrocytes [1-13C]glucose can be converted to
[3-13C]oxaloacetate by pyruvate carboxylase (PC). This will
lead to labeling of [2-13C]glutamate and [2-13C]glutamine,
and [4-13C]GABA. [1,2-13C]acetate can be converted to
[1,2-13C]acetyl-CoA. Labeled acetyl-CoA enters the TCA
cycle and can lead to formation of [4,5-13C]glutamate,
[4,5-13C]glutamine or [1,2-13C]GABA.
Injection of MK801 lead to metabolic changes in temporal
lobe only. Thus, no results from FCR are shown. In temporal
lobe there was an increase in the labeling of glutamate and
glutamine from both [1-13C]glucose and [1,2-13C]acetate,
compared to controls (Fig. 3A and B). Aspartate labeling from
[1-13C]glucose was increased in the MK801 treated rats,
whereas GABA labeling was unaltered.
As can be seen in Table 1, MK801 administration resulted in
an increase in the amounts of glutamate, glutamine and
succinate in temporal lobe. The amounts of GABA and
aspartate were unaffected (Table 1).
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Fig. 1. (A) 1H NMR spectrum of temporal lobe extract from rat injected with
MK801. Peak assignments; protons on 1, creatine C-3; 2, GABA C-3; 3,
aspartate C-3; 4, NAA C-3; 5, glutamine C-4; 6, succinate C-2 or C-3; 7,
glutamate C-4; 8, GABAC-2; 9, glutamine C-3; 10, glutamate C-3; 11, NAAC-
6. (B) 13C NMR spectrum of temporal lobe extract from rat injected with
MK801 together with [1-13C]glucose and [1,2-13C]acetate. Peak assignments;
1, creatine C-3; 2, aspartate C-3 (doublet); 3, aspartate C-3 (singlet); 4, taurine
C-2; 5, GABAC-2 (doublet); 6, GABAC-2 (singlet); 7, succinate C-2 or C-3; 8,
glutamate C-4 (doublet); 9, glutamate C-4 (doublet); 10, glutamate C-4 (sing-
let); 11, glutamine C-4 (doublet); 12, glutamine C-4 (singlet); 13, glutamate C-3
(doublet); 14, glutamate C-3 (singlet); 15, glutamine C-3 (doublet); 16,
glutamine C-3 (singlet). The singlets in the spectrum are mostly derived from
[1-13C]glucose and the doublets from [1,2-13C]acetate.
Fig. 2. Schematic presentation of isotopomers of glutamate, glutamine, GABA and aspartate derived from [1-13C]glucose (A) and [1,2-13C]acetate (B).
Table 1
Amounts of metabolites (mmol/g) in extracts from the temporal lobe of controls
and rats treated with MK801
Controla MK801
Glutamate 10.0  1.2 11.5  1.4*
Glutamine 3.6  0.5 4.3  0.6**
GABA 2.0  0.4 2.3  0.6
Aspartate 2.6  0.4 2.9  0.5
Succinate 0.7  0.2 0.9  0.2*
Animals were injected with saline (n = 8) or 0.1 mg/kg MK801 (n = 10)
intraperitoneally every day for six days. Amounts of metabolites were analyzed
with 1H NMR spectroscopy. Metabolites were quantiﬁed using the protons on;
glutamate C-4; glutamine C-4; GABA C-2; aspartate C-3; succinate C-2/3 (for
details see Section 2). The results are expressed as mean  S.D. and were
analyzed with the Student’s t-test.
a Values from Kondziella et al. (2005).
* p < 0.05 signiﬁcant difference between control and MK801.
** p < 0.02 signiﬁcant difference between control and MK801.
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Amounts of metabolites (mmol/g) in extracts from the temporal lobe of controls
and rats treated with MK801
Controla MK801
Glutamate 10.0  1.2 11.5  1.4*
Glutamine 3.6  0.5 4.3  0.6**
GABA 2.0  0.4 2.3  0.6
Aspartate 2.6  0.4 2.9  0.5
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Animals were injected with saline (n = 8) or 0.1 mg/kg MK801 (n = 10)
intraperitoneally every day for six days. Amounts of metabolites were analyzed
with 1H NMR spectroscopy. Metabolites were quantiﬁed using the protons on;
glutamate C-4; glutamine C-4; GABA C-2; aspartate C-3; succinate C-2/3 (for
details see Section 2). The results are expressed as mean  S.D. and were
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* p < 0.05 signiﬁcant difference between control and MK801.
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4. Discussion
NMR spectroscopy analyses of neurometabolites in brain
from MK801 injected rats, a model of NMDA/glutamate-
hypofunction and schizophrenia have provided valuable
information about disturbances in amino acid neurotransmitter
metabolism. Given once at 0.5 mg/kg, MK801 produced
mainly changes in the temporal lobe with increased glutamate
and glutamine concentrations and labeling from [1-13C]glucose
(Brenner et al., 2005). Similar changes were detected in the
present study, when MK801 was injected repeatedly at 0.1 mg/
kg every day for six days and changes were restricted to the
temporal lobe. However, using 0.5 mg/kg repeatedly (Kond-
ziella et al., 2005) instead of 0.1 mg/kg, resulted in changes in
the FCR, thereby mimicking alterations observed in patients
with schizophrenia (Bartha et al., 1997; Theberge et al., 2002;
Tebartz van et al., 2005).
4.1. Glutamate and glutamine concentrations
Repeated injection of 0.1 mg/kg MK801 increased gluta-
mate and glutamine concentrations and labeling in the temporal
lobe, but not in the FCR. However, with repeated high doses
(0.5 mg/kg) of MK801 no differences were found in the
temporal lobe, but glutamate was increased in the FCR
(Kondziella et al., 2005). In order to evaluate the signiﬁcance of
these ﬁndings for the understanding of glutamatergic function
in schizophrenia it is important to compare with results
obtained from patients. The latter analyses have to be done in
vivo, where assessment of glutamatergic neurotransmission is
difﬁcult. Recent developments in NMR spectroscopy offer the
opportunity to quantify a number of signals, including
glutamate and glutamine. To our knowledge, there are four
in vivo studies published in which absolute glutamate and
glutamine concentrations were measured using NMR spectro-
scopy technology (Bartha et al., 1997; Theberge et al., 2002,
2003; Tebartz van et al., 2005). In an early study Bartha et al.
(1997) reported increased glutamine levels in the medial
prefrontal cortex of never-treated schizophrenia patients.
Theberge et al. (2002) conﬁrmed this observation for the left
anterior cingulate and thalamus in a group of ﬁrst-episode
schizophrenia patients. In a second study, the same investi-
gators reported signiﬁcantly lower levels of glutamate and
glutamine in the left anterior cingulate of patients with chronic
schizophrenia, whereas Tebartz van et al. (2005) detected
higher glutamate and glutamine concentrations in dorsolateral
prefrontal cortex and hippocampus. However, the latter
authors found an unusually low glutamate concentration in
control patients and thus the relevance of this study is doubtful.
Taken together the ﬁrst three reports indicate that ﬁrst-episode
patients have an increased glutamine level in different areas of
the brain, whereas chronic patients have decreased glutamate
and glutamine levels in anterior cingulate. Animal models
of schizophrenia should mimic this. In the present study,
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increases were found in glutamate and glutamine in the
temporal lobe but not in the FCR. Thus, it appears that this
model does not show the same pattern as seen in schizophrenia
patients and mimics more the toxic effects of MK801 possibly
caused by increased glutamate in the extracellular space. In
line with this is the fact that low doses of MK801 in the present
study lead only to moderate hyperlocomotion alterations
compared with high doses (data not shown). Repeated
injection of the high dose (0.5 mg/kg) does, however, show
very similar results to those from ﬁrst-episode patients
(Kondziella et al., 2005) and might thus be a good model
for schizophrenia.
4.2. Astrocyte–neuron interactions
In the present study, labeling of glutamate and glutamine
was increased in the temporal lobe, whereas GABA labeling
was unchanged. It is possible to study astrocyte–neuronal
interactions by analyzing the labeling patterns from [1-13C]-
glucose and [1,2-13C]acetate in metabolites. A major role of
astrocytes in the adult brain is to support neurons metabolically
and the glutamate–glutamine cycle is well established
(Sonnewald et al., 1997). Astrocytes are essential in maintain-
ing the low glutamate levels in the synaptic cleft needed for
precise receptor-mediated functions (Danbolt, 2001). Extra-
cellular glutamate is taken up by astrocytes, in which it is
converted to glutamine. Glutamine is then transported to the
presynaptic neuron and converted to glutamate again. This
process appears to be enhanced in our study, since labeling of
both glutamate and glutamine from glucose, and thus mostly
neurons, is increased in the temporal lobe. Labeling from
[1,2-13C]acetate was also increased in glutamate and glutamine
in this area after repeated injection of 0.1 mg/kg MK801. Since
the transport system for acetate is mostly on astrocytes such
labeling originates from astrocytes (Waniewski and Martin,
1998). Taken together, these observations might be an
indication of increased glutamatergic function, which could
cause the neurotoxic effects of NMDA antagonism reported by
several authors (Olney and Farber, 1994; Farber et al., 1995,
1996, 1998). A similar increase in labeling of glutamate and
glutamine in the temporal lobe was reported by Brenner et al.
(2005) after injection of a single dose of 0.5 mg/kg MK801.
However, repeated high dose injections had no effect on
labeling in the temporal lobe but lead to a decrease in labeling
of glutamate and GABA from [1-13C]glucose in the FCR
(Kondziella et al., 2005).
Interestingly, localization of the changes in the metabolic
results is different than that of histologic results. Several
authors reported reversible vacuolization and other histologic
abnormalities conﬁned to retrosplenial cortex (RSC), which is
part of the FCR, with low doses, involving the temporal lobe
only when high doses were given (Olney et al., 1989; Wozniak
et al., 1996, 1998). Although the mismatch between metabolic
and histologically results seems surprising at ﬁrst glance, it
should be noted that the histological alterations were fully
reversible (Wozniak et al., 1996) and that altered cell structure
is not always identical with altered cell function.
4.3. Complex polysynaptic network impairments and the
kindling effect
Why do different doses of MK801 lead to impairment of
different brain areas?While a single high dose and repeated low
doses of MK801 lead to biochemical alterations in temporal
lobe, repeated high doses spared the temporal lobe largely, but
evoked signiﬁcant disturbances in the FCR. It is highly
interesting in this context, that MK801 directly injected into the
RSC, which is part of the FCR, does not produce the same
neurotoxic reactions as that seen with equivalent systemic
doses (Farber et al., 2002). This signiﬁes that NMDA receptor
blockade is required at one or more sites outside the RSC to
trigger these neurotoxic effects. Thus, polysynaptic network
impairments have to be considered. Possibly, different doses of
MK801 may have the same local effects in the FCR, but
different outcome in other non-FCR areas, whereby low doses
of MK801 may change polysynaptic chains in such a way that
metabolic disturbances are most pronounced in the temporal
lobe. In contrast, high doses of MK801 affect other
polysynaptic chains, leading to alterations in FCR. Since only
repeated doses, but not a single dose, of 0.5 mg/kg MK801 lead
to alterations in the FCR, one might postulate that the relevant
polysynaptic changes have to be sensitized, or in other terms,
‘‘kindled’’.
In conclusion; do repeated MK801 injections serve as a
model of schizophrenia? The answer is yes, if the chosen dose is
high enough. Repeated low doses (0.1 mg/kg) ofMK801mimic
the behavioral changes such as a slight hyperlocomotion and
increased pre-pulse inhibition (Schulz et al., 2001), but not the
neurochemical alterations seen in schizophrenia. Repeated high
doses (0.5 mg/kg) mimic both. In conclusion, repeated
injection of MK801 at 0.1 mg/kg appears to model the toxic
effects of NMDA hypofunction, whereas repeated administra-
tion of high doses (0.5 mg/kg) mimics the results observed in
ﬁrst-episode schizophrenia patients.
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1998). Taken together, these observations might be an
indication of increased glutamatergic function, which could
cause the neurotoxic effects of NMDA antagonism reported by
several authors (Olney and Farber, 1994; Farber et al., 1995,
1996, 1998). A similar increase in labeling of glutamate and
glutamine in the temporal lobe was reported by Brenner et al.
(2005) after injection of a single dose of 0.5 mg/kg MK801.
However, repeated high dose injections had no effect on
labeling in the temporal lobe but lead to a decrease in labeling
of glutamate and GABA from [1-13C]glucose in the FCR
(Kondziella et al., 2005).
Interestingly, localization of the changes in the metabolic
results is different than that of histologic results. Several
authors reported reversible vacuolization and other histologic
abnormalities conﬁned to retrosplenial cortex (RSC), which is
part of the FCR, with low doses, involving the temporal lobe
only when high doses were given (Olney et al., 1989; Wozniak
et al., 1996, 1998). Although the mismatch between metabolic
and histologically results seems surprising at ﬁrst glance, it
should be noted that the histological alterations were fully
reversible (Wozniak et al., 1996) and that altered cell structure
is not always identical with altered cell function.
4.3. Complex polysynaptic network impairments and the
kindling effect
Why do different doses of MK801 lead to impairment of
different brain areas?While a single high dose and repeated low
doses of MK801 lead to biochemical alterations in temporal
lobe, repeated high doses spared the temporal lobe largely, but
evoked signiﬁcant disturbances in the FCR. It is highly
interesting in this context, that MK801 directly injected into the
RSC, which is part of the FCR, does not produce the same
neurotoxic reactions as that seen with equivalent systemic
doses (Farber et al., 2002). This signiﬁes that NMDA receptor
blockade is required at one or more sites outside the RSC to
trigger these neurotoxic effects. Thus, polysynaptic network
impairments have to be considered. Possibly, different doses of
MK801 may have the same local effects in the FCR, but
different outcome in other non-FCR areas, whereby low doses
of MK801 may change polysynaptic chains in such a way that
metabolic disturbances are most pronounced in the temporal
lobe. In contrast, high doses of MK801 affect other
polysynaptic chains, leading to alterations in FCR. Since only
repeated doses, but not a single dose, of 0.5 mg/kg MK801 lead
to alterations in the FCR, one might postulate that the relevant
polysynaptic changes have to be sensitized, or in other terms,
‘‘kindled’’.
In conclusion; do repeated MK801 injections serve as a
model of schizophrenia? The answer is yes, if the chosen dose is
high enough. Repeated low doses (0.1 mg/kg) ofMK801mimic
the behavioral changes such as a slight hyperlocomotion and
increased pre-pulse inhibition (Schulz et al., 2001), but not the
neurochemical alterations seen in schizophrenia. Repeated high
doses (0.5 mg/kg) mimic both. In conclusion, repeated
injection of MK801 at 0.1 mg/kg appears to model the toxic
effects of NMDA hypofunction, whereas repeated administra-
tion of high doses (0.5 mg/kg) mimics the results observed in
ﬁrst-episode schizophrenia patients.
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